Content
Yahoo Finance News
09/16
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Checkpoint Therapeutics, Inc Checkpoint Therapeutics, In...
Yahoo Finance Community
09/16
Comment
Could someone compare the data from Keytruder below with the long term data? Results: Between 29 November 2017 and 25 September 2019, 159 patients were enrolled and treated with pembrolizumab (LA cohort, n 1⁄4 54; R/M cohort, n 1⁄4 105). The median time from the first dose to data cut-off date (29 July 2020) was 14.9 [interquartile range (IQR), 12.6-17.2] months for the LA cohort and 27.2 (IQR, 25.6-29.2) months for the R/M cohort. In the LA cohort, ORR was 50.0% [95% confidence interval (CI), 36.1% to 63.9%], including 16.7% of patients with a CR and 33.3% with a PR. In the R/M cohort, ORR was 35.2% (95% CI, 26.2% to 45.2%), including 10.5% of patients with a CR and 24.8% with a PR. Median DOR was not reached in either cohort. Grade 3-5 treatment-related adverse events occurred in 11.9% of patients....
Votes:
1
0
Quantexa News
09/18
Checkpoint Therapeutics Inc (CKPT) Stock's 0.13% Increase This Year: What's the Story?
B. Riley Securities has recently resumed Checkpoint Therapeutics Inc (CKPT) stock to Buy rating, as announced on July 14, 2022, according to Finviz . Earlier, on June 9, 2021, B. Riley Securities had...
Yahoo Finance Community
09/24
Comment
The SP drop most likely due to possible stock offering that they need to do. If FDA wasn't so slow and inefficient, a lot of these small cap companies with good drug candidates would survive without having to raise cash all the time while waiting for FDA. As far as CKPT is concerned, hopefully, if they are raising cash, it is the last one at firesale prices. Best way to contract increased share number is by adding to your share count at these prices....
Yahoo Finance Community
09/26
Comment
It's unlikely to be approved considering the fact they only did a phase one trial. It was a very robust trial with very good response data and high objective response rates. Also there's been extended long-term data and good pharmacodynamic modeling. Which means there is an improved chance based purely on the phase one trial. But it's still incredibly rare to be approved with only a phase one and usually only if there's high unmet need and there isn't thanks to Keytruda and Opdivo. They're also running out of cash and going to have to do a capital raise or a debt offering in January or February. I wish they were likely to be approved and had a better cash position because then it would be an easy buy. I'm leaning towards shorting this though or buying long puts. Does anyone have any other thoughts? Even disagreeable ones?...
Quantexa News
10/01
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 CHECKPOINT THERAPEUTICS, INC. (Name of Issuer)...
Quantexa News
10/03
XTX Topco Ltd Makes New Investment in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
XTX Topco Ltd acquired a new position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities an...
Yahoo Finance Community
10/07
Comment
Look at the institutional holdings info from 6/30. 23 companies increased position, 12 decreased with only 4 firms selling out completely of positions, totaling less than 20k shares. Vanguard, Blackrock, State Street added a total of 469k shares to their holdings. 8 new companies adding. I’m liking this trend. I’m not expecting we get word of FDA approval until December 28 to give Checkpoint insiders the ability to buy as many shares as possible while trying to keep the SP suppressed....
Yahoo Finance Community
10/08
Comment
The annual incidence of primary squamous cell carcinoma (SCC) in the US is 1.8 million cases per year, 2% of the cancers metastasize, there are about 36,000 cases of metastatic SCC of the skin in the US yearly. The cost for one year of Keytruda for treatment of metastatic cutaneous SCC is $200,000. If CKPT gets just 10% of the US market, first year sales will be $720 Million Dollars if priced similarly to Keytruda. This estimate does not count the cases of locally advanced cutaneous SCC, 40,000 cases annually in the US. The global incidence of cutaneous SCC outside the US is 2.4 million cases annually of which 48,000 will metastasize. If approved in December, Cosibelimab will be used to treat both metastatic and local advanced cutaneous SCC....
Votes:
5
0
Quantexa News
10/08
Checkpoint Therapeutics Inc (CKPT)'s latest performance is not what we had anticipated
Checkpoint Therapeutics Inc (NASDAQ: CKPT) kicked off on Monday, up 9.91% from the previous trading day, before settling in for the closing price of $2.22. Over the past 52 weeks, CKPT has traded in a...
Yahoo Finance Community
10/09
Comment
I just sold the rest of my FBIO to go all-in on CKPT. If there is the possibility of an acquisition, then you would want to be holding CKPT for the "share swap". Everything comes down to CKPT in the end, in the entire FBIO playbook if you ask me. No future for them without it. An acquisition can also happen at any time and prior to the PDUFA date. Either way, the PDUFA goal date is getting close so the price will probably climb either way soon. Many reasons why this is now the time to go all-in in my opinion. At the very least least, we could see what's called a "killer acquisition", which is when a company acquires another company with the intent of preventing their product from ever coming to market. For example, REGN would acquire CKPT with no intent to ever actually use Cosi, but …...
Votes:
3
1
Quantexa News
10/14
Renaissance Technologies LLC Has $166,000 Stock Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Renaissance Technologies LLC lessened its holdings in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) by 71.5% during the 2nd quarter, Holdings Channel reports. The firm owned 77,200 share...
Yahoo Finance Community
10/14
Comment
It's extremely tough for Shorts to closeout their positions right now. Remember, when you short a stock, in order to liquidate your position, you have to "Buy to Cover", which means each time a Short wants out, they have to do a "Buy order", which of course makes the price go way up. And with low volume like this it can be disastrous for Shorts. The price can double in a blink if they all want out of the stock at once. And with a major catalyst looming right now that is just a few weeks away, it's about the worst case scenario for people who are Shorting. I can see why there is a target of $20....
Votes:
6
1
Yahoo Finance Community
10/14
Comment
CKPT was in low $40's about 2 years ago before all the share dilutions.. so even with the increased share count, it should still be much higher than the current $2.50. Since FDA decision is just around the corner and there has been no indication or rejection or problems by FDA...
Votes:
2
0
Yahoo Finance Community
10/16
Comment
Here is an rough analysis of potential sales based on AI generated data if Cosibelimab is approved for the treatment of metastatic and locally advanced cutaneous SCC in December. The annual incidence of primary squamous cell carcinoma (SCC) in the US is 1.8 million cases per year, 2% of the cancers metastasize, there are about 36,000 cases of metastatic SCC of the skin in the US yearly. The cost for one year of Keytruda for treatment of metastatic cutaneous SCC is $200,000. If CKPT gets just 10% of the US market, first year sales will be $720 Million Dollars if priced similarly to Keytruda. This estimate does not count the cases of locally advanced cutaneous SCC, 40,000 cases annually in the US. The global incidence of cutaneous SCC outside the US is 2.4 million cases annually of which 48,000 will metastasize....
Votes:
3
0
Yahoo Finance Community
10/16
Comment
They probably already had the re-inspection and it's probably just a matter of days now before the approval. On another note, for some bizarre reason, the Short Interest is at 11%, so we're seeing the beginning of a significant short squeeze. When you have relatively low volume during a short squeeze, there is no telling how high the price can go. Almost like Gamestop, lol. Why they would short this with a Blockbuster Drug approval looming is a very bad move. This is a perfect storm for a massive multi-bagger with the short squeeze added in....
Votes:
4
3
Yahoo Finance Community
10/16
Comment
I don't really want a buyout. They can just share the space with the others and with Keytruda. Will be fun to watch that. A few years ago CKPT had a target price at $96, and who knows, maybe they can actually hit it. Keep in mind, CKPT's immediate Q1 revenue could be around $150 - $200 million because of this approval. That's a massive windfall of money to immediately bring in. They could potentially knock on the 1 billion door by year-end. This is going to totally disrupt the competitors currently in the space and I could see why they would want to prevent that from happening, but the overall share price will do a lot better without a buyout....
Votes:
1
1
Yahoo Finance Community
10/17
Comment
Something massive is about to happen. I think we all know that. God only knows how high this will run, but this is the Big One in my opinion. I could easily see this in the $20 - $40+ range in the coming weeks. One reason why the price will go unusually high is because the float is so low for a Blockbuster Drug approval like this....
Votes:
1
3
Yahoo Finance Community
10/17
Comment
I need to correct myself for the Complete Response numbers for Cosibelimab ("Cosi") vs. Keytruda. Cosi has a Complete Response rate of 25% compared to Keytruda's 17% with local advanced cSCC. That is a huge difference between the two and Cosi appears to be Best in Class by a rather large margin. It's a no-brainer that it will be the preferred therapy with those types of blowout numbers compared to the competition, especially since the CEO plans to market it at a reduced price. Merck and REGN are going to hate losing that revenue, lol. Total Blockbuster FDA approval ahead for CKPT. If there is a buyout, it better be a minimum of $25.00 on the share swap....
Votes:
2
1
Yahoo Finance Community
10/18
Comment
There are currently 4,380,000 shares sold short. Those guys must really be going crazy right now, lol. Scary stuff for them. Even if half of the Shorts try to cash-out, that's still 2 million shares that they have to buy back in order for that to happen. When you Short a stock, and if you want out of that stock, you then have to "Buy to Cover", which means they have to Buy their way out of this mess, lol. The Short Squeeze alone should put this in the $5 - $10 range. That's the way these things work. This short squeeze is a total gift on top of the pending Blockbuster FDA Approval. Also, remember the stock symbol DRUG from a few days ago with the 3,000% gain (run) from $1 to $30 in just 1 day? I would not doubt it if CKPT does something similar to that....
Votes:
3
1
Yahoo Finance Community
10/18
Comment
Don't forget this fun fact: The last time a drug similar to CKPT's entered the space for treating cSCC, they were immediately bought out. in July, 2022, REGN acquired Libtayo for 950 million. REGN'S Libtayo is comparable to Merck's Keytruda. Well, guess what? CKPT's "Cosibelimab" is superior to both of them by a significant margin and CKPT could potentially steal 100% of that multi billion dollar market share ( i think the market is around 2B). So, if REGN acquired Libtayo for 950 million, what do you think the valuation of CKPT is? It will sell for a lot more than than Libtayo, no doubt about that....
Votes:
3
0
Yahoo Finance Community
10/18
Comment
of course they must be incompetent not to have covered themselves, but do you believe that they are so incompetent? if they are institutional I really don't think they are so stupid since even we small ones would not have opened short in view of the approval, so who are these incompetent people?...
Yahoo Finance Community
10/18
Comment
I sold all FBIO and loaded up on CKPT. There won't be much benefit to holding FBIO if CKPT is acquired. A share swap would take place when CKPT is acquired, and that share swap obviously can't include FBIO shares. They will receive nothing. In fact, in my opinion, holding any FBIO instead CKPT is a very bad move. I recently had 140,000 shares of FBIO, so I have nothing against them. CKPT is just the obviously place to be in this one. No interest in playing the DERM approval as well....
Votes:
1
0
Yahoo Finance Community
10/18
Comment
It is not useful to check CKPT price action over the years with its stock price since it has had a reverse split and multiple stock dilutions, but if you check its market cap over past few years, at the end of 2021 which was way before approval it had a market cap of about 320 Millions which is about 2.4 times today's... so once its drug is approved the SP should bounce to well above current level. If we only get to $320M MC, then SP should be about $7...... Enjoy...
Votes:
1
1
Yahoo Finance Community
10/19
Comment
The stock will probably just keep climbing for a long time to come. I would love to see $6 - $10 range before the approval comes down. Company Earnings (and guidance) is in only 22 days from now on 11-11. That's when we will get a lot of big info regarding commercialization, partnership, and maybe full blown FDA approval at that time, depending if the approval happens that week. Either way, many stocks will have a run-up in price as Earnings /guidance approaches, and with a company like this that's on the brink of a major blockbuster FDA approval, I think we can expect the price to continue to rise sharply for the foreseeable future, and to probably go quite high over the coming weeks. This also increases the timeline for an acquisition to take place. Some acquisitions actually happen before the final approval in cases like these....
Votes:
6
1
Yahoo Finance Community
10/25
Comment
“These longer-term results for cosibelimab presented at the ESMO Congress demonstrate a deepening of response over time, with higher objective response and complete response rates than initially observed at the primary analyses, and continue to expand the evidence supporting the efficacy and safety of cosibelimab as a potential new treatment for advanced cSCC,”——- friends, let this science sink in- hand wringing over 3, 4 bucks a share is silly, just sayin’…...
Votes:
6
0
Yahoo Finance Community
10/27
Comment
I see many (objective and subjective) similarities between tgtx ( Briumvi) and Ckpt (Cosi).Both drugs are best-in-class drugs, both drugs have same PDUFA date (12/28), both drugs got delayed in their process to approval (4 months for Ubli, 11 months for Cosi (due to CMO issues) and above all, both companies ( same people at the helm) have same marketing approach ( i.e. selected and targeted approach to maximize potential with small but efficient Sales Team). Both drugs have huge and still growing TAM. Both drugs can be used in many indications (as single agent or in combination). Both companies are well managed.The current weak point of CKPT is its financial situation. Funds raising through offering and/or partnering and/or non-dilutive process will happen in the foreseeable future (before and/or after Cosi approval).Of course Cosi has to get the FDA nod first. I have no doubt about it even though nothing …...
Yahoo Finance Community
10/27
Comment
I an new here. Got here because someone alerted me on the $CRMD board.I have some moderate success with CRMD ( bought at around $7.5). If CKPT's issue is ONLY the manufacturing (CMO), then I see CKPT has a decent chance of succeeding. BTW, CRMD had a couple of CRLs issued by the FDA before finally approving it. I hope CKPT gets the nod in the coming months.CRMD has gone from the lows of $4 to $13 (as of last Friday).What are the price targets of the experts here? Thank you for sharing your thoughts!(I do not place too much weight on the analysts' targets as they have other motives like underwriting subsequent secondaries etc)....
Votes:
1
2
Yahoo Finance Community
10/28
Comment
Edited this post. Disregard the Oct 31 announcement. Thanks for wake up call fifi. To many bios to keep up with. This is not the correct stock regarding the Oct 31 FDA announcement. Sorry all. Will leave it to help clear up any confusion....... Oct 31 announcement should leak soon if not already. Volume big with a nice open gave me lots of optimism but this sell down is concerning when one throws in the leak probability....
Votes:
1
1
Yahoo Finance Community
10/28
Comment
Short interest is still about 10% , which means they think they still have some time to play with stock as they don't forsee FDA decision sooner than the end of December... but at the same time if approval comes sooner then they need to scramble and cover, or let it go up and short more then cover when it retreates to make up for the earlier shorts......
Votes:
2
1
Quantexa News
10/29
Assessing the Risk and Potential of Checkpoint Therapeutics Inc's (CKPT) Stock
The stock of Checkpoint Therapeutics Inc (CKPT) has seen a 19.62% increase in the past week, with a 68.75% gain in the past month, and a 58.16% flourish in the past quarter. The volatility ratio for t...
Quantexa News
10/30
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Stock: Can It Surge Further?
In the last trading session, 2.1 million shares of the Checkpoint Therapeutics Inc (NASDAQ:CKPT) were traded, and its beta was 1.31. Most recently the company's share price was $3.84, and it changed a...
Yahoo Finance Community
10/31
Comment
From JUNE so hopefully given Lillys approval manufacturing issues well addressed!As Korean CDMO giant Samsung Biologics continues to ink production pacts around the globe, the company has added another billion-dollar feather to its cap.In a public disclosure posted Tuesday, Samsung Bio revealed a new manufacturing accord with a large, unnamed U.S. drugmaker worth 1.46 trillion Korean won (about $1.05 billion). The deal represents more than 39% of Samsung Biologics' total sales haul from last year, which clocked in at around 3.7 trillion won (roughly $2.7 billion).Samsung Bio and the unnamed company signed a letter of intent around the deal on June 5. The latest production accord is set to run through the end of 2030, according to the public disclosure, though the final manufacturing period may “vary according to the agreement between the two companies,” Samsung Biologics said.Samsung Bio has been on a winning streak in recent months, bucking the …...
Votes:
2
0
Quantexa News
10/31
Should Checkpoint Therapeutics Inc (NASDAQ: CKPT) Revive After A -9.12% Drop From Highs?
During the last session, Checkpoint Therapeutics Inc (NASDAQ:CKPT)'s traded shares were 2.39 million, with the beta value of the company hitting 1.31. At the end of the trading day, the stock's price...
Quantexa News
10/31
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Sees Large Increase in Short Interest
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling...
Quantexa News
10/31
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Sees Large Increase in Short Interest
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 4,610,0...
Quantexa News
11/01
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Rises By 5.3%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 4,610,000 shares, a growth o...
Quantexa News
11/01
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update
Checkpoint Therapeutics, Inc. ( – ) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 4,610,000 shares, a growth of 5.3% from the September...
Quantexa News
11/02
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 5.3% in October
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest to...
Quantexa News
11/02
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 5.3% in October
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totallin...
Quantexa News
11/02
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03%
Checkpoint Therapeutics Inc (NASDAQ:CKPT) shares, rose in value on Friday, November 01, with the stock price up by 2.03% to the previous day's close as strong demand from buyers drove the stock to $3....
Yahoo Finance Community
11/05
Comment
I don’t like it when ppl tout other stocks on a message board. But I’m gonna do it myself, bc I’ve owned CKPT for a long time and I like this group of folks. It’s furthest from biotech/pharma possible and I’ve owned shares for 4 years. RECAF owns drilling rights to a vast portion of the Kavango Basin in Namibia and northeastern Botswana. Results from a very important test well are coming down in 1-3 weeks, and there is little doubt that this is going to be huge. It will dwarf any returns from CKPT. With a little effort you can read up on the history and what is about to happen. Go ahead and downvote me I do not care. I hope 1-2 ppl have enough curiosity to at least check it out. Even a small position could be the best thing you ever did. I have 72K shares …...
Votes:
3
2
Yahoo Finance Community
11/05
Comment
The stock has the market cap of $160mil just 2 months before an expected FDA approval for a cancer drug that has $1B potential!So why is that? Is it because:1) Investor's worried about another CRL?2) Investor's not believing the market potential after the approval?3) With Keytruda already dominating the market, investors are worried if there is room for CKPT's drug? worried that the oncologists will not be prescribing CKPT and just stick with Keytruda?My opinions are as follows:1) I am not worried about CRL. The drug WILL be approved in December.2) The market potential is less than what is projected... But there is SOME potential!3) Yes, I am worried about this but still there is always a room for second source for a similar medicine (in this case a second source to Keytruda in indications applicable to CKPT)So in conclusion, CKPT may not reach $3B market cap (20x from here) …...
Votes:
3
0
Quantexa News
11/06
Checkpoint Therapeutics Inc (CKPT): What Is Good About Stock?
Checkpoint Therapeutics Inc (NASDAQ:CKPT) has a beta value of 1.28 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $148.56M, closed the last trade...
Yahoo Finance Community
11/07
Comment
Astellas Pharma had a drug rejected by FDA due to the same manufacturing issues. They resubmitted on May 30th with the decision date of November 9th. Astellas drug got FDA approval 3 weeks earlier on October 18 !!! Not much longer for CKPT, I am guessing by the end of November or very early December ......
Votes:
6
0
Quantexa News
11/11
Wealth Enhancement Advisory Services LLC Acquires 80,000 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Wealth Enhancement Advisory Services LLC lifted its position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) by 160.0% in the 3rd quarter, according to its most recent Form 13F filing wit...
Yahoo Finance Community
11/11
Comment
while the FDA aims to be efficient, the due date provides a structured timeline that allows for a thorough, unbiased, and transparent review process. Approving drugs before this date could compromise the integrity and safety of the approval process. I would not expect an earlier approval...
Votes:
4
0
Yahoo Finance Community
11/11
Comment
This gradual drop has nothing to do with FDA’s decision for a simple fact that there has been no announcement. I don’t believe in leaks and if there were a negative leak it wouldn’t sell off this way. So what’s left?? What could cause a drop like this? Gradual and slow. Not an expert, but i would say maybe the management is selling shares to keep the lights on!!...
Yahoo Finance News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Checkpoint Therapeutics, Inc Tue, Nov 12, 2024, 4:30 PM 10 min read In This Article: FBIO +2.55% FBIOP...
Quantexa News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 12, 2024 at 04:31 pm EST Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass. Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkp...
Quantexa News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Share Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“C...
Quantexa News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoi...
Quantexa News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial r...
Quantexa News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoi...
Yahoo Finance Community
11/12
Comment
Cosibelimab longer-term results presented in advanced cutaneous squamous cell carcinoma (cSCC) presented at ESMO Congress 2024 demonstrated ORR of 54.8% (n=109) compared to Keytruda KEYNOTE-629 trial ORR of 50% in the locally advanced cSCC (n=54). The complete response rates were 25.8% with Cosibelimab compared to 4% with Keytruda in the same population. The results are inline with the recent article published in Nature, and the article highlighted PD-L1 antibodies (ex. Cosibelimab) are more effective than PD-1 antibodies (ex. Keytruda). With the manufacturing issues sorted out, I think the safety and efficacy data is in favor of CKPT!...
Votes:
4
0
Yahoo Finance Community
11/12
Comment
The reason for the jump is that due to the exercise of warrants, they don't need to raise cash until after FDA decision as announced today. So hopefully, we should see a steady rise until the FDA announcement. Market was nervous about a pre FDA dilution.......
Votes:
6
0
Yahoo Finance Community
11/12
Comment
So we have all discussed the potential of this drug (TAM about $1Billion) and whether it will get approved by the FDA. I'm less worried about it not getting approved as was mentioned some time ago, the manufacturer Samsung had other drugs receive CRLs and those drugs have now gotten the nod from the FDA and have been approved. So I'm feeling good that they have addressed the manufacturing issues stated in the CRL. With that being said, what will happen to these shares once approval happens. Here is what I think. MRK knows that it's patent is running out of runway on Keytruda while there are numerous other large Oncology BP like BMS, ABBV, Roche, J&J, etc that there is no way that someone is not going to kick the tires here and buy this company outright. Please note that the very low end for valuation based on drug …...
Votes:
8
0
Quantexa News
11/12
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoi...
Quantexa News
11/14
Navigating the Volatility of Checkpoint Therapeutics Inc's (CKPT) Stock
In the past week, CKPT stock has gone up by 6.79%, with a monthly gain of 31.03% and a quarterly surge of 67.19%. The volatility ratio for the week is 9.69%, and the volatility levels for the last 30...
Quantexa News
11/14
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
It has been nearly a year and a half since my previous Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ) article . Then, I highlighted the company's flagship candidate, cosibelimab, or "Cosi," and its pot...
Quantexa News
11/15
Should Checkpoint Therapeutics Inc (NASDAQ: CKPT) Rally After -5.03% Drop From High?
Checkpoint Therapeutics Inc (NASDAQ:CKPT)'s traded shares stood at 1.08 million during the last session, with the company's beta value hitting 1.28. At the close of trading, the stock's price was $3.7...
Yahoo Finance Community
11/16
Comment
SNDK just got FDA approval this past Friday after the close for their drug. BTW, their PDUFA date was December 26th. So for those thinking it’s not possible for an early announcement for CKPT you are dead wrong. Let’s watch what will happen to SNDX on Monday at the open. Hopefully they soar higher and this could be a harbinger for what’s to come for CKPT....
Votes:
6
0
Yahoo Finance Community
11/19
Comment
I am guessing that the people who bought the last offering and then exercised the warrants in November are cashing out half their shares. If you add the initial offering price and the warrant execution price you get about 3.47. So they can sell half, get their capital out, and let the other half ride on the hopes of an approval. That would be between 5-6 million shares of selling pressure. When that’s done this should rise...
Votes:
5
2
Quantexa News
11/19
Investigation announced for Long-Term Investors in shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) over potential Wrongdoing
11-20-2024 12:01 AM CET | Business, Economy, Finances, Banking & Insurance Press release from: Shareholders Foundation An investigation on behalf of current long term investors in Checkpoint Therape...
Quantexa News
11/20
What is HC Wainwright's Estimate for CKPT FY2024 Earnings?
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) – Research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for Checkpoint Therapeutics in a report issued on Thu...
Yahoo Finance Community
11/21
Comment
MIST; $1.75; Upon potential approval of its tachycardia heart drug we should see a market cap of $400 - $600M and a share price of $10 - $15. This reflects a conservative approach, using 3 x US potential revenue while neglecting the pipeline value and outside US market opportunities. A non-dilutive financing to support the launch is already in place. Moreover, we have been in a very narrow trading range of about 1,50$ for 10 months which was just broken with a strong upside move and with increasing trading volume and public visibility. Technically at a golden cross, signaling a major breakout. More buzz on the street will follow, driving the share price appreciation further. No risk for bad news in the near term and solid financials with ample cash on hand....
Yahoo Finance Community
11/22
Comment
5 weeks to go. I think we will get a slightly early decision. 12/28 is a Saturday and you know very well anybody that can take off Christmas to New Years will, so nothing will be happening in the department that makes that decision. I think we hear something before Christmas....
Votes:
3
0
Quantexa News
11/23
Does Checkpoint Therapeutics Inc (NASDAQ: CKPT) Still Look Attractive After A 9.33% Selloff Last Week?
During the last session, Checkpoint Therapeutics Inc (NASDAQ:CKPT)'s traded shares were 0.84 million, with the beta value of the company hitting 1.28. At the end of the trading day, the stock's price...
Yahoo Finance Community
11/25
Comment
Worldwide PD-(L)1 Sales in 2025 are expected to be $50 Billion. Cosibelimab will be best in class when approved. With a current market cap of 200 million, I don't see how this doesn't get bought out for at least $20 a share (a small $1 billion). Even with all the warrants out there, this drug is way better than Keytruda. If they only did $2 billion in sales by 2026, this is worth over $50 a share. There's only 50M shares plus warrants. Someone tell me I'm wrong, but I don't think so....
Votes:
9
2
Yahoo Finance Community
11/26
Comment
Pilgrims: let the below comment from the CEO sink in….you can’t get a much more promising outlook than this…..just sayin’……“These longer-term results for cosibelimab presented at the ESMO Congress demonstrate a deepening of response over time, with higher objective response and complete response rates than initially observed at the primary analyses, and continue to expand the evidence supporting the efficacy and safety of cosibelimab as a potential new treatment for advanced cSCC,” said James Oliviero, President and Chief Executive Officer of Checkpoint.”...
Votes:
10
0
Quantexa News
11/26
Checkpoint Therapeutics Inc (CKPT) Shares Are Up 84.02% So Far This Year
Checkpoint Therapeutics Inc (NASDAQ:CKPT) has a beta value of 1.29 and has seen 2.32 million shares traded in the last trading session. The company, currently valued at $212.67M, closed the last trade...
Yahoo Finance Community
11/27
Comment
The problem here is that the management has not provided any real guidance in terms what they plan to do when approval is granted!! Approval alone is not enough. Need a lot of money to launch a new drug and we don’t have any money. That’s not an inviting situation for big investors to step into, and the reason the sp is not where it should be....
Votes:
4
3
Quantexa News
11/27
Checkpoint Therapeutics Inc (CKPT) Stock: A Closer Look at the Analyst Ratings
Additionally, the 36-month beta value for CKPT is 1.31. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it...
Yahoo Finance Community
11/27
Comment
I can’t find anything from the company about drug launch or commercialization. They aren’t hiring anyone. They don’t have a sales/marketing officer. Even if you’re nearly broke, you would hire a couple people that could build a sales team. Nothing. Am I missing something? If I’m not, then what are the odds they intend to sell on or shortly after approval?...
Yahoo Finance Community
11/27
Comment
Management has had a year to find a partner to market Cosibelimab contigent upon approval. Hopefully, when Cosidelimab is approved management will announce that they have sold the international rights to Cosidelimab and/or a buyout. If there still is no plan in place, the stock will temporarily spike upon approval and then go down unfortunately....
Votes:
4
0
Yahoo Finance Community
11/28
Comment
A number of thoughts regarding CKPTSince it failed FDA approval last year, CKPT has been in delicate cash situation. They had to offer twice shares and included some warrants . All dilutive : shares and in the money warrants adding about 25m shares potentially.FDA decision and subsequent dilution has occulted a rather positive news regarding Cosi : there was nothing wrong with the clinical trial and overall the compound to be approved. On the other hand pivotal and longer term studies has shown a real efficacy which can compare to the Keytruda rockstar. Obviously CKPT have been distracted by the scarcity of cash lately. As they said in Q3 conference, they raised just enough to complete the year till the PDUFA and a little bit beyond, meaning they have a plan for quickly after approval, and a good one, not an ATM or a Warrant offer plan giving little visibility.To …...
Votes:
4
0
Quantexa News
11/30
Checkpoint Therapeutics Inc (NASDAQ:CKPT) Shares Surged 27.09% In A Week – But Will They Keep Going Up?
In last trading session, Checkpoint Therapeutics Inc (NASDAQ:CKPT) saw 0.8 million shares changing hands with its beta currently measuring 1.33. Company's recent per share price level of $4.41 trading...
Polygon News
12/02
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend
The article discusses the global surge in cancer cases, particularly among people under 50, and the efforts of biotech companies to develop new therapies to combat this trend. It highlights recent pro...
Yahoo Finance Community
12/03
Comment
Lets keep things in perspective. This has been the pattern for CKPT for over 6 months now. Just a few weeks ago we were all crossing our fingers this would break $4.00. My opinion is that the market manipulators are just creating buying opportunities before bumping it again....
Votes:
4
0
Yahoo Finance Community
12/03
Comment
I googled ckpt for the reason the shares dropping today. This came up. The company received concerns about the drug CRL from the fda. Potential issues with the drug approval process leading to uncertainty about the future revenues and impacting investors confidence . I don’t know if this information is accurate. Did anyone else come across this information. I can’t get a date and time when this came out. There’s nothing on yahoo and fidelity about this....
Votes:
1
7
Yahoo Finance Community
12/03
Comment
It's not a good day for biotechs in general and not CKPT issues. There is also no news regarding FDA. The FDA news will be coming from FDA in the next couple of weeks and not from imaginary reports. Shorts need to cover soon and fast. Expect volatility until the REAL FDA announcement .....
Votes:
1
0
Yahoo Finance Community
12/03
Comment
South Korea, where Cosibelimab will be manufactured or the company manufacturing it, is based on, just declared martial law today so I am guessing a lot of companies with similar situations as CKPT had the same reaction and caused some investors to get spooked.Martial Law has been already revoked....
Votes:
1
0
Yahoo Finance Community
12/03
Comment
I think all biotechs especially small companies went down because Samsung Pharmaceuticals is located in South Korea. There is concern if the manufacturing of various drugs will be affected by the President of S. Korea declaring martial law. Ten hours later this was blacked by the S. Korean congress and the President rescinded the declaration. Might be a one off opportunity to buy more shares. GLTA...
Votes:
4
0
Quantexa News
12/04
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Sees Large Growth in Short Interest
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totallin...
Quantexa News
12/04
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalli...
Quantexa News
12/04
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Expands By 8.5%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 6,030,000 shares,...
Yahoo Finance Community
12/09
Comment
I’m not going to read too much into today’s movements, because there’s Monday morning blues all around the small cap bio market. That being said, I agree with William that we haven’t seen big volume buying from the Street. This week will be important. If you’re long, you may need to get comfortable with a longer term perspective. I’m holding my position regardless of how it trades over the next few months....
Votes:
1
0
Yahoo Finance Community
12/09
Comment
It is getting closer to FDA decision and some investors are getting nervous and it is understandable. These price fluctuations are expected, one can check other small biotechs with similar situations and they always go up and down sharply before they get their FDA responses....
Votes:
3
0
Quantexa News
12/10
Investors must take note of Checkpoint Therapeutics Inc's (CKPT) performance last week, which was -7.89%.
On Monday, Checkpoint Therapeutics Inc (NASDAQ: CKPT) opened lower -5.70% from the last session, before settling in for the closing price of $4.21. Price fluctuations for CKPT have ranged from $1.36 t...
Yahoo Finance Community
12/10
Comment
Just an observation. A lot of Bios in my watchlist down today. Looking at the other drugs that have been announced by the FDA this month, some of those decisions are trending 7-10 days earlier than their pdufa dates. I'm rolling the dice and saying we have an announcement next week....
Votes:
2
0
Yahoo Finance Community
12/11
Comment
My take is Ckpt is waiting for approval to maximize any potential opportunities. I think there should be multiple opportunities they are considering including partnership as well as buyout. The silence is creating doubt in the price action. JMHO GLTA...
Votes:
2
0
Quantexa News
12/12
Walleye Capital LLC Invests $148,000 in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Walleye Capital LLC acquired a new position in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) in the third quarter, according to the company in its most recent disclosure with the Securit...
Quantexa News
12/12
FDA Decision On Checkpoint Therapeutics' Cosibelimab Due On Dec.28 - Will Second Time Be The Charm?
Checkpoint Therapeutics Inc.'s investigational drug, cosibelimab, proposed for the treatment of advanced cutaneous squamous cell carcinoma (cSCC), is under review by the FDA, with a decision anticipat...
Quantexa News
12/12
PVG Asset Management Corp Increases Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
PVG Asset Management Corp increased its position in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) by 9.2% in the third quarter, according to the company in its most recent filing with th...
Quantexa News
12/12
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares Purchased by PVG Asset Management Corp
NASDAQ:CKPT – Free Report ) by 9.2% during the third quarter, HoldingsChannel reports. The institutional investor owned 149,870 shares of the company's stock after purchasing an additional 12,676 shar...
Quantexa News
12/13
Checkpoint Therapeutics Inc (CKPT) Stock: What the Analysts are Saying
The stock has a 36-month beta value of 1.32. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for CKPT is 41.17...
Quantexa News
12/13
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
On December 13, 2024, the Food and Drug Administration approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metas...
Polygon News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
Checkpoint Therapeutics announced that the FDA has approved UNLOXCYT, the first and only PD-L1 blocking antibody for the treatment of advanced cutaneous squamous cell carcinoma. UNLOXCYT has demonstra...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(TM) (cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cos
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
Checkpoint Therapeutics, Inc 13 min read In this article UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 20...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
December 13, 2024 at 06:16 pm EST WALTHAM, Mass. Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administrat...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Check...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™...
Quantexa News
12/13
PRESS RELEASE: Paid Content from GlobeNewswire - Mobile . The AP news staff was not involved in its creation. Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™...
Quantexa News
12/13
Pay Attention to this Trade Activity as Checkpoint Therapeutics Inc (CKPT) last week performance was -8.87%
Checkpoint Therapeutics Inc (NASDAQ: CKPT) started the day on Thursday, with a price decrease of -4.52% at $3.80, before settling in for the price of $3.98 at the close. Taking a more long-term approa...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™...
Quantexa News
12/13
Exciting Advancement as UNLOXCYT Gains FDA Approval for Treatment
Author Lucas Young Updated : 12-13-2024 06:30 PM Checkpoint Therapeutics Announces Breakthrough FDA Approval WALTHAM, Mass. - Checkpoint Therapeutics, Inc. has received exciting news regarding its...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Check...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
In This Article FBIO FBIOP CKPT Checkpoint Therapeutics, Inc UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., D...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval Of UNLOXCYT™ (Cosibelimab-Ipdl)
MENAFN - GlobeNewsWire - Nasdaq) UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Chec...
Quantexa News
12/13
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™...
Yahoo Finance Community
12/13
Comment
the company believes the initial indications could lead to $1.6B in U.S. sales for Cosi, and the potential worldwide expansion will expose them to a global immunotherapy market that exceeds $35B annually. Clearly, a $1B+ in peak sales would suggest the company should get off to a strong start after Cosi's launch....
Quantexa News
12/13
FDA Oks Checkpoint Therapeutics' UNLOXCYT For Advanced Cutaneous Squamous Cell Carcinoma treatment
Checkpoint Therapeutics Inc. (CKPT) has announced that the U.S. Food and Drug Administration (FDA) has granted approval for UNLOXCYT (cosibelimab-ipdl). This medication is designed for adults with met...
Yahoo Finance Community
12/13
Comment
The statement below from the PR sure seems odd. From an efficacy and clinical viewpoint this drug was basically approved last year but final approval was held up due to manufacturing issues. It was a slam dunk right? So you would think the company was totally prepared to roll it out soon after approval. Yet according to the today's PR they are 'currently developing a commercial launch plan'. IMO there could only be three reasons for not being ready to roll out a commercial launch plan this Monday. 1) Incompetent management or 2) Partnership with Big Pharma to handle marketing/sales or 3) Buyout. "We are excited about the approval of UNLOXCYT and are currently developing a commercial launch plan."Given that they are cash poor and don't have a marketing plan ready, my guess is a partnership will be announced early next week....
Votes:
4
0
Quantexa News
12/13
Checkpoint Therapeutics, Inc. Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)
December 13, 2024 at 06:15 pm EST Checkpoint Therapeutics, Inc. announced that the U.S. Food and Drug Administration (?FDA?) has approved UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with...
Yahoo Finance Community
12/14
Comment
Chatgpt gives me a 60% chance of an offering.... Weighing the Scenarios Offering Likelihood: Pros: Immediate cash, maintains independence, and avoids rushing into less favorable partnerships. Cons: Potential dilution for existing shareholders and increased operational risk due to lack of infrastructure. Probability: 60%. Likely in the short term, especially if no partnership discussions are underway. Partnership/Buyout Likelihood: Pros: Reduces commercialization risk, provides access to established resources, and could unlock greater long-term value. Cons: Loss of some control over the drug or the company. Probability: 40%. More likely as a medium-term strategy if the company needs additional support for global launches or faces execution challenges....
Votes:
1
2
Quantexa News
12/14
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U....
Yahoo Finance Community
12/14
Comment
As much as I would love to hear the same answer you’re looking for. I realize that it was only yesterday that they had the approval. And that the plan was to wait another 2 weeks for it. So I am just going to wait until January for a win and probably wait longer if I want the big win....
Votes:
2
0
Yahoo Finance Community
12/14
Comment
Besides William, how many on here are aware that TGTX CEO Mike Weiss is on your board? I hold TGTX shares but no CKPT. We were better positioned post-approval for Briumvi than you are for Cosi and we have been fighting shorts and “analyst” games for two years (our short interest is STILL higher than yours and Briumvi is a blockbuster with tremendous sales growth). So don’t be surprised if they take you down some. Monday morning will be very interesting whether they have debt, partnership lined up or if they’ll be issuing more shares. Also, while I’m inclined to think Weiss is more focused on getting TGTX sold, don’t be surprised at speculation of TGTX + CKPT, which could then get your shares bought out multiple times. Congrats and good luck....
Votes:
2
0
Yahoo Finance Community
12/14
Comment
Out of the woods now shorts! Plenty of cash to operate with next year and beyond. Easy money in revenue from shorts covering at high prices. $20 price target and now it's believable and coming true. No sleep for dumb shorts this weekend. Geddy up!...
Votes:
1
0
Yahoo Finance Community
12/14
Comment
Don’t know what anyone is thinking here!! Consensus is that this is a $1BiLLION a year drug. Let’s say for arguement sake $800,000,000 ONLY . Now PS/ Sales $800,000,000 \40,000,000 shares equals $20.00 per share On a purchase it would be 21/2 -3 time sales Equals $50.00/ $70.00 per share respectively . Ladendburg Thaan in 2021. Came up with a price of $80.00 per share and that is how they got this calculation. I’ll be happy with $25.00. This company has no money of significance. They should sell for $20-$25.00 per share by MONDAY to the Katrina guys as their patents is off in the years . Monday may open between $8.00-$10.00 With 16-18% of float short could ad $3.00’- 4.00 above that . ....
Votes:
4
0
Yahoo Finance Community
12/14
Comment
I tried to replay the September H W Wainwright conference “fireside chat”, but the video is apparently no longer available. Regardless, at that time, Oliviero stated that approval wasn’t “a matter of if, but when.” He also stated that they had already been in discussions with a partner, and that on approval everything would change, or something to that effect. I expect another announcement this week. If anyone has that video, or took notes, please chime in here....
Votes:
2
0
Yahoo Finance Community
12/14
Comment
Let's say this approval gives CKPT a perceived MC of $1B. TGTX could borrow $300M against their company and buy a percentage ownership in CKPT. No dilution to either company. TGTX would be able to pay it off in a couple years and CKPT would have money to move forward. If TGTX wanted to sell their company their CKPT ownership would be a desirable asset for the purchaser or that assist could be passed on to TGTX shareholders in the form of CKPT shares. Seems a win win for everybody....
Votes:
1
0
Yahoo Finance Community
12/14
Comment
They've hired no marketing director or related personnel from what I can tell. If correct then it seems obvious they have a partner in hand who can market the drug. After all, they've had a year to put a deal together. If there is upfront money, likely, they won't need to dilute now....
Votes:
4
0
Yahoo Finance Community
12/14
Comment
I see many debates for the market estimates for cosi on this board, and I feel obligated to clarify the numbers. CKPT clearly states the US market for PD1/PDL1, exceeds $1billion/annum. This marker size accounts ONLY cSCC. Why? B/c FDA approval covers only cSCC at the moment. The drugs in cancer space are validated for the easiest path to get the initial approval for (CKPT chose cSCC), and then gets expanded with additional use (after the initial FDA approval): the process of expansion takes years, but is a clear path with clinical trials. It is perfectly reasonable to expect that the cosi use will be expanded similarly to that of Keytruda b/c they target similar pathway, but cosi does it way better. Everyone in cancer space wants the best in class, so think that the ultimate market of cosi will be the same as Keytruda. Keytruda sales (forget the market …...
Votes:
9
0
Yahoo Finance Community
12/14
Comment
For the fun of it, as memory serves, the foundational work for this branch of science is from, again as memory serves, Peter Lindsey (I think that was his name, Peter?), who did some basic work at a company called Immunex back in the 1980s? early 90s in Seattle, working with Ledbetter as I recall, Ledbetter being the PI so to speak. It was a matter of how people read Peter's work, and Jim (Allison) among others read it what proved to be correctly ultimately yielding the whole checkpoint therapy field. Jim and Ledbetter were buds. I don't know if Peter gets mentioned much, and maybe it was really Ledbetter and he just was first author of the moment. I have no idea. I think it was Goldstein who actually cloned CTLA-4 a few years earlier, but Lindsey defined the ligand (B7.1, before there was such a thing as B7.2, …...
Votes:
3
0
Yahoo Finance Community
12/15
Comment
There are unlimited options for additional indications for cosi. And for a best in class MOA in the field - the interest to get this antibody tested for further indications is big. For me this is the best in class MOA to work with immune checkpoints in oncology. I personally think that fishing for ligands is better than blocking receptors, because cells frequently react by upregulation of receptors when these are diminished or blocked. A natural mechanism of cellular resistance, in particular of tumor cells with aberrant genetics. However, if ligands are removed - there is no compensatory cellular response to expect, thus, this is the better mechanism of action. The value of cosi (the AB) now may already exceed $1B, and this value will be unleashed by licencing deals or abuyout beyond $1B. Just MHO. All the best....
Votes:
5
0
Yahoo Finance Community
12/15
Comment
How much cash does CKPT have? Last report said $4.7M in September but they took in $9.2M cash in November through the exercise of warrants. $13.9M less what they spent in the last 3 months. They may have plenty of cash to last if they are licensing out Unloxcyt or just selling the company....
Yahoo Finance Community
12/15
Comment
This is totally within yahoo guidelines . I suggest everyone read the in depth analysis below on these yahoo posts of Louis and Edward Chekmeven. Yahoo is censoring me for point ing this out. Such incompetent depriving their subscribers from reading post already below . What imbeciles...
Yahoo Finance Community
12/15
Comment
Heard the CEO on a podcast, granted 3 years old, but he said he wants to license or direct launch in the US and partner outside the US. Unless his position has changed, I am expecting this to be licensed out then subsequent expansionary approvals to be launched by Checkpoint in the US....
Yahoo Finance Community
12/15
Comment
COSI is FDA approved now and that's the biggest strength ; manipulations ,shortings would have very little effect now. CKPT shall survive and thrive by its own merit from now onwards , everything else is frills. $ 10 SP is no joke anymore only matter of time. GLTA...
Yahoo Finance Community
12/15
Comment
One cautionary note: Dermatologists prefer slicing people up, it's a cash-cow for them. I had personal experience with this. This is also what sunk Dermtek (besides incompetent management there). So a lot of kickback pharma dollars need to go to those quacks to prescribe Unloxcyt....
Votes:
2
0
Yahoo Finance Community
12/15
Comment
could the ceo be so incompetent to not announce a partnership or bo tomorrow morning. i find it hard to believe, but anything is possible. i thought mw of tg was the worst. we will know tomorrow if oliveira joins his ranks or rises and actually acts in the best interest of the shareholders....
Yahoo Finance Community
12/15
Comment
That was the most BLATANT censorship ever by the idiots at Yahoo . Just states when Nasdaq begins to trade and repeated what post in front of me said . Shame on them Here’s what I said “ Nasdaq begins pre trading at 4:00 am and we will know indications and hope that mgt post Ms their plans for the passed drug before that .fact all over this post 16.8-18 % short squeeze. Everyone on this site posted this shame on these censors for absolutely within guidelines...
Yahoo Finance Community
12/15
Comment
Interesting, I spoke to the “go to” Oncologist in our town last night at a function I attended. I told him about this approval and the study results/efficacy verse its competition, and he extremely interested and is going to look into it for his patients. In other words, this should be pretty easy treatment to sell....
Yahoo Finance Community
12/15
Comment
You all looking for big numbers and I think you will be very disappointed. You’re only talking about sales in the USA over One billion dollars. That’s not a lot when there’s competition involved. If we were talking about 10-15 billion dollars per year in the USA. That would change the picture. Back to reality. We are only talking over one billion dollars per year....
Votes:
1
2
Yahoo Finance Community
12/15
Comment
possibilities for monday am: 1. bo 2. partnership for europe - depending on how much we get upfront, we could go up to 5-6 range and then come back to 4s as the day progresses. 3. dilution - we open under 3 and trade between 2.75-3.25. 4. no news - we trade sideways around 4, but in expectation of dilution ah we close in the red. so unless we have a clear bo, we aren't going to make a ton of money tomorrow...in fact our portfolio could see a 20-30% decline. lets hope it is a bo....
Votes:
3
3
Yahoo Finance Community
12/15
Comment
Let's appreciate the management, medical teams and support staff and celebrate with them as well. Criticisms aside there is much credit for developing an efficacious treatment and for seeing FDA requirements through. Work is yet to be done, yes, thankfully a prosperous future for company and patients has arrived....
Votes:
5
0
Quantexa News
12/16
Checkpoint Therapeutics (CKPT) Hits New Heights: What's Next for the FDA-Approved Immunotherapy?
Checkpoint Therapeutics Soars in Premarket Trading: A Key Milestone for the Company In an exciting turn of events, Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) saw its stock price rise by an impressi...
Polygon News
12/16
US Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December'
U.S. stock futures are trading higher ahead of the Federal Reserve's decision this week, with the Nasdaq 100 index setting new record highs. Analysts expect a 25 basis point rate cut, and the market i...
Quantexa News
12/16
Checkpoint Therapeutics : Announces FDA Approval of UNLOXCYTTM (cosibelimab ipdl) Form 8 K
December 16, 2024 at 07:04 am EST Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT TM (cosibelimab-ipdl) UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutan...
Quantexa News
12/16
**Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT for Treatment of Advanced Cutaneous Squamous Cell Carcinoma**
On December 13, 2024, Checkpoint Therapeutics, Inc. disclosed in an 8-K filing that the U.S. Food and Drug Administration (FDA) has given the green light to UNLOXCYT (cosibelimab-ipdl) for addressing...
Quantexa News
12/16
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cu...
Quantexa News
12/16
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s CKPT Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for...
Quantexa News
12/16
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candi...
Quantexa News
12/16
FDA Approves Cosibelimab-Ipdl for Adult Patients with mCSCC or laCSCC
The FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who...
Quantexa News
12/16
Checkpoint Therapeutics Sees Unusually High Options Volume (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the target of unusually large options trading on Monday. Investors acquired 7,866 call options on the company. This represents an in...
Quantexa News
12/16
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Sees Large Increase in Short Interest
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 6,570,000 shares, a grow...
Quantexa News
12/16
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update
NASDAQ:CKPT – Get Free Report ) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 6,570,000 shares, an increase...
Yahoo Finance Community
12/16
Comment
Keytruda has 27 indications, we currently have 1 indication that had better results and lower toxicity than Keytruda! Today's trading is not indicative of the future that Unloxcyt has. This has the potential to be a big cancer fighting drug, don't lose sight of the forest for the trees!...
Votes:
9
0
Quantexa News
12/16
Checkpoint Therapeutics Inc (CKPT) Stock Price and Analyst Predictions
The stock has a 36-month beta value of 1.32. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for CKPT is 41.17...
Quantexa News
12/17
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
Vandana Singh 2 min read In This Article On Friday, the FDA approved Checkpoint Therapeutics, Inc.'s (NASDAQ: CKPT ) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cS...
Quantexa News
12/17
Checkpoint Therapeutics Sees Unusually High Options Volume (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) saw some unusual options trading activity on Monday. Stock traders bought 7,866 call options on the company. This represents an increase o...
Quantexa News
12/17
Checkpoint Therapeutics Target of Unusually Large Options Trading (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the target of unusually large options trading on Monday. Investors bought 7,866 call options on the company. This is an increase of...
Yahoo Finance Community
12/17
Comment
16 million volume yesterday and they couldn't nuck a buck off it. They are in trouble, they need to jump in rather than waste time in driving it down to get it for cheaper than it already is. This is guaranteed to go up, partnership or takeover....
Votes:
2
1
Quantexa News
12/17
No matter how cynical the overall market is Checkpoint Therapeutics Inc (CKPT) performance over the last week is recorded -14.61%
A new trading day began on Monday, with Checkpoint Therapeutics Inc (NASDAQ: CKPT) stock price down -7.63% from the previous day of trading, before settling in for the closing price of $3.67. CKPT's p...
Yahoo Finance Community
12/17
Comment
If you were going to go into business with a company that was waiting for federal approval of their product, wouldn’t you wait until that approval came through before committing? I would. Perhaps the process just hasn’t played out yet. The approval came Friday. Only after that point would I consider going into business with a company that had a “50/50 chance” of approval, as posted by some. If I were in talks with another party and was obligated to sign a non disclosure then it would certainly explain the radio silence. Don’t you think?...
Votes:
7
0
Yahoo Finance Community
12/17
Comment
FBIO has the controlling majority in CKPT and an equity interest. Thus, FBIO is responsible to decide about cash infusion and motivated to unleash the intrinsic value of the approved drug. Thus, FBIO will tailor a financing deal in it's best interest - and this is a non-dilutive measure....
Yahoo Finance Community
12/17
Comment
the problem is that with that fund of financial bandits they are even capable of diluting the small shareholders even under the dollar and then make a regrouping and then another dilution I have seen this thing done several times where they are inside (the criminal fund) they have destroyed the small shareholders then the white knight arrives and with a few dollars the company is lost unfortunately I fear that this thing will happen here because the collapse is too big and I don't think it will stop for weeks...
Yahoo Finance Community
12/17
Comment
As disappointing as an approval drop is try to take emotions out of it. Look at the volume yesterday and already almost 2M an hour in today. This has largely been held by retail so ask yourself who is picking up all these shares..? this has been shaken out to near perfection and if yesterday repeats nearly the entire float worth of volume exchanging hands… partnership announcement is coming....
Votes:
5
2
Quantexa News
12/18
Stock Traders Buy High Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) was the target of some unusual options trading activity on Monday. Stock investors purchased 7,866 call options on the company. This is an...
Yahoo Finance Community
12/18
Comment
Ckpt letting shorts babble and whine their negatives. Gotta know they have big plans. When they want to they'll shovel the dirt on shorts. They have the Ace card now and just weighing options. Many Biofarms are courting them now. Be ready for positive news very soon....
Votes:
7
1
Yahoo Finance Community
12/19
Comment
I think someone should call police to have them do a wellness check on CEO. Clearly something fishy is going on, maybe even a hostage situation. On a side note I can't even get on their website. Checked Linkden for job postings, nothing. Same for indeed nothing...
Votes:
1
1
Yahoo Finance Community
12/19
Comment
I saw this in stocktwits, maybe we can all send an email to IR. Dear lnvestor Relations I hope this letter finds you well. As a shareholder of Checkpoint Therapeutics, I am writing to express my concerns regarding the lack of communication about potential partnerships for the new drug approval process. The CEO previously stated that the company was actively seeking potential partnerships to support the new drug approval. However, to date, no announcements have been made regarding any such partnerships. This lack of communication has led to uncertainty and concern among shareholders about the progress and strategic direction of this critical initiative. I would appreciate it if the company could provide an update on the status of these partnership efforts and clarify the steps being taken to secure the necessary support for the new drug's approval. Transparent and timely communication is essential to maintaining investor confidence and demonstrating the …...
Votes:
5
0
Yahoo Finance Community
12/19
Comment
This silence is OK for now. Maybe, as some speculate, there are negotiations underway for Partner or BO. That would warrant silence. Or they are really working a plan to commercialize. Having seen some companies bungle this, I'm OK if they take the time, just get it right....
Votes:
8
0
Yahoo Finance Community
12/19
Comment
Maybe FBIO will just have CKPT commercialize the drug through an equity offering of ordinary common shares. After all the class A common owned by FBIO give them voting control over CKPT and the anti dilution feature of the class A means that the FBIO equity stake is not effected by issuing any amount of ordinary common no matter how large. So FBIO could then effectively have the ordinary shareholders pay 100 percent of the cost of commercialization through dilution, while FBIO maintains it current equity stake ( about half ) and pays nothing....
Votes:
1
0
Yahoo Finance Community
12/19
Comment
Usually, FDA approval is accompanied by share offerings within a day, especially if the company has to do it. That's why there was an immediate short attack on Monday, then by Wednesday they got nervous and started to cover some, and market meltdown did help out. Now, no one is sure what's happening. The fact there has not been a shares offering is a good sign as possible partnership news may be coming... we shall see....
Votes:
6
0
Yahoo Finance Community
12/19
Comment
With all these free shares getting thrown around among all the congratulatory back slappers, wouldn’t it be in their best interest to drive the price down for before issuance and then in true capitalistic fashion, manipulate the news to let it pop after?...
Yahoo Finance Community
12/19
Comment
One possibility for the news delay is loss taking may be more advantageous this year, as opposed to potentially more favorable taxes on capital gains next year. Therefore stock appreciation 12/31 and Jan 2025 is more tasty to insiders and MMs....
Votes:
2
1
Yahoo Finance Community
12/20
Comment
Good Morning CKPT relatives. Typically, a crazy rough market for speculative stocks—-options Friday. Wishing everyone sanity and patience. Let’s hope Mgmt who has also struggled this year with FDA, has a plan. Let’s support each other not make things worse by bashing a Company we believed in to invest our $$$...
Votes:
4
1
Quantexa News
12/20
Checkpoint Therapeutics Inc (CKPT) average volume reaches $1.26M: Are the Stars Lining Up for Investors?
As on Thursday, Checkpoint Therapeutics Inc (NASDAQ: CKPT) started slowly as it slid -5.60% to $3.37, before settling in for the price of $3.57 at the close. Taking a more long-term approach, CKPT pos...
Yahoo Finance Community
12/20
Comment
Downgrade for Merck BMO Capital Markets has downgraded Merck to market perform from outperform, citing uncertainty about the company’s succession plans for its blockbuster oncology drug Keytruda.The investment firm said the downgrade was based on commercial overhangs, such as the company’s Gardasil franchise in China, and the “need for additional clarity on how the company plans to fill the Keytruda gap” with federal drug price negotiations and biosimilars approaching.“Given a mounting skepticism across Pharma, we see MRK shares potentially stuck in limbo over the next 12 months with more attractive options available elsewhere along the value/ growth axis,” BMO added....
Votes:
6
0
Yahoo Finance Community
12/20
Comment
CKPT can still be used as a secondary drug for other indications if doctors deem it as necessary but a bigger pharma with deep pockets , size and patient population etc they can easily add more indications with quicker trials since safety and other profile is already established and approved. There is no need for large scale phase 3 and all they have to do is go against existing standard care versus ckpt and possibly combinations and prove it works. They may also use that set for patent like keytruda to milk billions.Yes generic is an option after 2028 but a big pharma need to step in now and explore all routes to garner a good share of the market in 2 years along with meticulous planning to how best they can use CKPT drug to extend their patent and revenue stream without wasting too much time.Not sure if Merck …...
Votes:
2
0
Yahoo Finance Community
12/20
Comment
The market cap, according to this site, is only $183 million. This makes very little sense, considering that the drug, which has huge potential, is now approved. The only thing that I can come up with is (1) the stock price is under $5, which is a hard stop for most institutions and (2) there is uncertainty over the plan/financing. If a solid plan is put forward, the stock price could quickly jump above $5, which could trigger large-scale institutional buy-in, which would then trigger short covering and FOMO. I'm other words, a massive bull run....
Votes:
3
0
Yahoo Finance Community
12/20
Comment
On December 18 gray divested 268,432 shares of common stock at an average price of 4.01 per share it says the sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock as per the company, corporate policiesGray retains ownership still of one032,754 shares which include restricted shares that best overtime...
Quantexa News
12/20
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average...
Quantexa News
12/20
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average...
Quantexa News
12/20
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $1,076,412.32 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average...
Yahoo Finance Community
12/21
Comment
Well those tax-related sell are a false alarm in my bell, however they do explain the downwards pressure we witnessed right after the announcement. Long term capital gain is less taxed than income, therefore there was 100% incentive for those guys to sell while the SP was low, 100% incentive for those guys not to make the SP explode before tax selling. Now that it’s done, let’s see how they manage their capital gains next week ;-)...
Quantexa News
12/21
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 268,432 Shares
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an aver...
Quantexa News
12/21
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 268,432 Shares of Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CFO William Garrett Gray sold 268,432 shares of the firm's stock in a transaction on Wednesday, December 18th. The shares were sold at a...
Yahoo Finance Community
12/21
Comment
"As of September 30, 2024, approximately $65.7 million of the securities remains available for sale through the Checkpoint 2023 S-3"We all know $ 66 M are not enough to build a Sale team and market Cosi (I know it's not Cosi anymore but I like Cosi).CKPT still have the remaining $ 66 M from the current 2023 Shelf available.I beg the question " Where will the much needed funds to market Cosi come from ? "Partnership for all or part of the financing needsRoyalty Loan for all or part of the financing needsLoan or Upfront from a Sister entity which is CFP ( follow my gaze )Use of the remaining $ 66 M mixed with one of the above-mentionned optionsorCKPT gets BO ( before or after being duly capitalized)It's anyone guess. I guess we will soon know. Interesting times ahead....
Votes:
2
0
Yahoo Finance Community
12/21
Comment
FDA approval is the biggest achievement of CKPT rest will follow in due course. Very effective cancer drug that can be expanded in many types of cancer treatment like keytruda . This is a rare find and under the radar stock. Very high potential to give great returns in the years to come....
Votes:
4
0
Quantexa News
12/21
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells 220,230 Shares of Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 220,230 shares of Checkpoint Therapeutics stock in a transaction that occurred on Thursday, December 19th....
Yahoo Finance Community
12/22
Comment
Well those tax-related sell are a false alarm in my bell, however they do explain the downwards pressure we witnessed right after the announcement, with more than 1m shares sold open market in a short time span. Long term capital gain is less taxed than income, therefore there was 100% incentive for those guys to have a low SP at the time of the pre-planned tax sell, and 100% incentive for those guys to have the good news happen after the pre-planned tax sell. Now that it’s done, let’s see how they manage their capital gains next week ;-)GLTA and Merry ChristmasPS : Edited for more clarity...
Quantexa News
12/22
Virtu Financial LLC Takes Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Virtu Financial LLC purchased a new position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) during the third quarter, according to its most recent Form 13F filing with the Secu...
Quantexa News
12/22
Virtu Financial LLC Buys New Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Virtu Financial LLC purchased a new position in shares of Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) during the third quarter, Holdings Channel reports. The fund purchased 13,605 shar...
Quantexa News
12/22
William Garrett Gray Sells 268,432 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
NASDAQ:CKPT – Get Free Report ) CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $4...
Quantexa News
12/22
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 220,230 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an...
Quantexa News
12/22
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 220,230 Shares
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 220,230 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, December 19th. The shares...
Yahoo Finance Community
12/22
Comment
Good morning- answer to some questions here . Exercising options is taxable as ordinary income at that time . Also many Companies have tax related sales planned . Probably, this planned tax sale by executives was set taking in account the December 28th approval possibility. However it came 2 weeks early and the sales had been set . If they cancelled in anticipation of any deal after December 29, that would possibly amount to insider trading and major lawsuits . It is also possible that any deals set up were for subsequent to the December 28th original approval date . The question now is - ?? Have other deals become more lucrative since the EARlY APPROVAL . What is really mismanagement is the failure to address these sales and a conference with analysts regarding non In depth disclosure of what is transpiring other than general indications and where the approval …...
Yahoo Finance Community
12/22
Comment
I reached out to IR and below is their response. I am going to hold and be patient. Thank you for your email. With the exciting recent announcement of the FDA approval of UNLOXCYT, our focus remains on developing a commercial launch plan, including assessing potential partnerships or other types of corporate development transactions as we've previously disclosed. We ask that you remain patient with us as we go through this phase – rest assured the management team and Board of Directors remain committed to creating value for shareholders. We expect to provide additional information when we have a material update. Best regards, Checkpoint Therapeutics, Inc....
Votes:
17
0
Yahoo Finance News
12/23
Checkpoint Therapeutics Insider Sold Shares Worth $3,074,764, According to a Recent SEC Filing
PREMIUM Checkpoint Therapeutics Insider Sold Shares Worth $3,074,764, According to a Recent SEC Filing MT Newswires Mon, Dec 23, 2024, 4:19 AM In This Article: CKPT -5.60% James F Oliviero III, Direct...
Yahoo Finance News
12/23
Checkpoint Therapeutics Insider Sold Shares Worth $1,076,412, According to a Recent SEC Filing
PREMIUM Checkpoint Therapeutics Insider Sold Shares Worth $1,076,412, According to a Recent SEC Filing MT Newswires Mon, Dec 23, 2024, 4:19 AM In This Article: CKPT -5.60% William Garrett Gray, Chief...
Quantexa News
12/23
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $1,076,412.32 in Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CFO William Garrett Gray sold 268,432 shares of the company's stock in a transaction on Wednesday, December 18th. The stock was sold at...
Quantexa News
12/23
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 220,230 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock...
Quantexa News
12/23
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $744,377.40 in Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 220,230 shares of the firm's stock in a transaction dated Thursday, December 19th. The shares were sold a...
Yahoo Finance Community
12/23
Comment
now they do speculative trading and then in a little while they will announce a monster issue of shares with enormous dilution and all the small shareholders will be burned. This is how it works with that criminal fund that is inside you will see everything organized. It's a classic. If the company was serious it would have already intervened to avoid this speculation but it's clear that...,,,,,,,,,,,...
Votes:
2
6
Yahoo Finance Community
12/23
Comment
Fact, the CEO transferred 900,000 shares into an irrevocable trust for his minor children. Do you really think he would go through the trouble of setting that up? If there wasn’t a bigger plan here come on people think about it he’s gonna take care of his own first And everyone else comes second so it’s time to be patient or pick up more stock. It’s not time to ship when you’ve been waiting. This long. This company is not going to diluted shares because the CEO wouldn’t go through the trouble of doing that for his own family before that happens....
Votes:
7
0
Quantexa News
12/24
Check out this: Checkpoint Therapeutics Inc (CKPT) could be on the verge of a big rally
Checkpoint Therapeutics Inc (NASDAQ: CKPT) is 54.59% higher on its value in year-to-date trading and has touched a low of $1.38 and a high of $4.50 in the current 52-week trading range. The question b...
Quantexa News
12/24
Last month's performance of 2.02% for Checkpoint Therapeutics Inc (CKPT) is certainly impressive
Checkpoint Therapeutics Inc (NASDAQ: CKPT) on Monday, plunged -5.60% from the previous trading day, before settling in for the closing price of $3.75. Within the past 52 weeks, CKPT's price has moved...
Yahoo Finance Community
12/24
Comment
On March 2024, Dr. Amir Sharma was appointed to CKPT's Board to assist with the development and commercialization of the organization’s initiatives. Currently, he holds a remote position at Vera Therapeutics. Prior to this, he held an on-site position at Alexion Pharmaceuticals, a subsidiary of AstraZeneca. Just a thought, but a lot of deals come down to relationships....
Votes:
4
1
Yahoo Finance Community
12/26
Comment
I can see lot of us are getting restless and rightly so looking at the CKPT mgt's unusual silence ; but we must take solace as the main hurdle of FDA approval has been achieved ( it takes more than 5 yrs and huge investment for any drug to get FDA approval). The merit of the drug COSI is great and it has the potential of becoming a blockbuster drug in future. This is a buy and hold for getting many fold returns in a year or so. GLTA...
Votes:
10
0
Yahoo Finance Community
12/27
Comment
It is clear that FBIO has no intention of selling or making a commercial participation but only of increasing the controlling share in order to be able to take all the possible profits in the years to come, therefore it will order CKPT to make a large issue of shares with the dual purpose of creating a commercial network to directly sell the drug and at the same time reduce to zero the share of the small shareholders who will thus be burned and will not see any advantage from the approval, buying shares of a subsidiary involves this risk, therefore they have ...........
Votes:
1
3
Yahoo Finance Community
12/27
Comment
the talk about fbio forcing ckpt to dilute and gia so fbio can collect royalties makes no sense. fbio is a mere 50m mc company. even in a fire sale of ckpt at 250m, they will add 25M to their coffers. why would they wait 5-10 years for the same amount in royalties when they can get it all right now. so fbio forcing a dilution makes no sense. now if nobody wants ckpt even at 250m, that is a different story. we will know next week for sure....
Yahoo Finance Community
12/27
Comment
Don't think that FBIO does anything with ckpt other than to issue new shares at CKPT in order to finance the launch of cosi and the operational cash need there. FBIO has an anti-dilution-provision with CKPT, thus, FBIO's stake will be unchanged thereafter. FBIO will profit from the future income at CKPT by collecting royalties on the product revenue and by increasing the stake in CKPT at a rate of 2.5% per year via free shares. What could be a better scenario for FBIO? None....
Votes:
1
0
Yahoo Finance Community
12/28
Comment
fbio will not interfere in either a ckpt sale or a partnership agreement. get that out of your head. they stand to gain more in case of a sale or partnership than forcing ckpt to dilute and gia. the approved indication for cosi is only a 1B US market. other indications will take time n money and by the time it gets approved for other indications the market will be riddled w generic K. hence, the reason for the bride waiting at the altar for 2 weeks now. jpm coming up soon and I won't be surprised if either ckpt or tgtx or both get gobbled up....
Votes:
2
0
Yahoo Finance Community
12/28
Comment
All the subtle little negativities about not surviving. Silly little girls. FDA just dealt ckpt a straight flush while dealing shorts a pair of duces. Glad I'm long and hope shorts are deeper that deep. When it happens hedges will do everything to halt the move up and their bankruptcies....
Votes:
11
0
Yahoo Finance Community
12/30
Comment
After a full year of delay from FDA's CRL, CKPT finally gets it FDA approval and investors on this board are immediately complaining that there is no deal announcement. Were you expecting a deal announcement just days after FDA approval?Doesn't work like that. If you are going to sell your drug to the highest bidder, it will take time (months) to go through the process. Even if there is ongoing negotiations prior to FDA approval, things change once approval happens. There is no way you work out terms prior to approval and then immediately sign an agreement immediately after approval. If that happens, you can be sure management had worked out an extremely bad and desperate deal. Put it this way, if a basketball star signs with Nike before he wins a championship, the terms won't be as good as if he waited and won a major championship and then …...
Votes:
12
0
Quantexa News
12/31
A major move is in the offing as Checkpoint Therapeutics Inc (CKPT) market cap hits 163.59 million
Checkpoint Therapeutics Inc (NASDAQ: CKPT) kicked off on Monday, down -4.15% from the previous trading day, before settling in for the closing price of $3.49. Over the past 52 weeks, CKPT has traded i...
Yahoo Finance Community
12/31
Comment
There’s a lot of delayed announcements with other stocks as well. I too was looking forward to timely news here, especially when it was anticipated. This week is the last trading week of ‘24 and eoy tax-loss selling is dominating the market. Tomorrow the market is closed. I find the holidays reduce volume and every company I’ve ever worked with slows down, many to a long halt. Thursday/Friday still some new year’s hangover. Look to the following week for any real progress. If none then, well all the hemming and hawing might actually mean something....
Quantexa News
01/04
State Street Corp Buys 23,000 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
State Street Corp raised its stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) by 32.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 94,424...
Yahoo Finance Community
01/04
Comment
I think the market for approved use is very crowded. Approval is validation, real value won't be realized until someone with deep pockets gets involved. And fund combo trial. They had a phase 3 lung cancer trial going in 2022 that they stopped they said for the Russian Ukraine war and studies taking place in Russia. But I think financial situation was such they opted for the skin cancer trial. Lots of possibilities....
Yahoo Finance Community
01/05
Comment
The he real question is what kind of deal goes down here . If the mgt are lame duck inept guys beholden to FBIO we are all in trouble. But if mgt of CKPT I considering independent deal benefitting ALL Shareholders not only themselves and FBIO , then we have a good chance gettting a $5.00 price to $7.50. - All is contingent how independent the CKPT mgt is ????...
Votes:
1
0
Yahoo Finance Community
01/10
Comment
I really cant imagine, that this drug doesnt raise interrest of established pharma companies. Approval is done with results, better than keytruda. Also safety profile is favourable. Not to speak about possible uses in other cancer fiels. We speak about hundrets of mullion dollars. I say give them time to do proper negotiations to find the best solution for all sides...
Votes:
3
0
Yahoo Finance Community
01/10
Comment
If Mr. Gray’s employment with the Company is terminated by the Company without “cause” or he resigns for Good Reason not in connection with a change in control (as defined in the Agreement), he will receive severance consisting of twelve (12) months of current base salary, payable beginning on the sixtieth (60 th ) day following the termination date, with such first payment comprising all salary accrued from the termination date through the date of payment. In addition, he will receive: (i) partial accelerated vesting of all unvested equity awards with respect to the same number of shares that would have vested if Mr. Gray had continued in employment for one year after the termination date and to the extent any vested equity awards are stock options, Mr. Gray will have twelve (12) months from the date of termination in which to exercise such options and (ii) if Mr. Gray …...
Quantexa News
01/11
Geode Capital Management LLC Buys 124,787 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Geode Capital Management LLC raised its stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) by 41.2% in the 3rd quarter, according to its most recent 13F filing with the Secur...
Yahoo Finance Community
01/11
Comment
The newly disclosed 8K gives light on modifications made for the CFO employment contract in case of change in control. Why do it now in your opinion ? The Change in Control scenario offers the most generous severance and equity benefits, while the death or disability scenario provides more limited benefits :Severance Pay: The most substantial severance pay is provided in the second scenario (Change in Control), with a lump sum of 150% of base salary and bonus, compared to 12 months of salary in the first scenario and 4 months in the case of death or disability.Equity Vesting: Full acceleration of equity awards occurs in the second scenario (Change in Control), while partial acceleration is provided in the first and third scenarios.Health Insurance: The health insurance benefits are consistent in scenarios 1 and 2, with the company covering COBRA premiums for up to 12 months, while no specific mention …...
Votes:
2
0
Yahoo Finance Community
01/14
Comment
Holding a small position here, in at $3.07. How much belief in what Yahoo has listed as the 1 year estimated PPS should I believe? I am not sure how they arrive at that number, and I don't have much knowledge as far as doing research as I should. If it reaches what they anticipate it to be ($18), i'd be a happy camper!...
Yahoo Finance Community
01/15
Comment
Patience brothers and sisters. It takes 8-12 years on average for a drug to be approved (from IND to BLA/NDA). Covid is history, but think of the disruption to clinical trials during the period between 2020-2022, in addition to the patent cliff many large pharmaceuticals are seeing in the next 3 years. Companies such as Merck, AstraZeneca, and BM need to build their cancer portfolios. My only question is how cosi might be conjugated with other drugs for new indications besides squamas, thereby increasing its value. I feel safe buying more shares and think it might dip to $3 before a buyout. It may not be a 10 bagger but it could be a solid play with little downside risk because the molecule has value !...
Votes:
12
0
Yahoo Finance Community
01/16
Comment
BioPharmaDive story about PD-1 class drugs. "A few years ago Summit Therapeutics scoured the globe for a cornerstone asset. Executives examined some 140 medicines before zeroing in on a cancer therapy discovered by Akeso, a China-based drug developer.The resulting deal in December 2022 was met with little fanfare and even criticized by investors at the time. “This is boring,” Dave Gancarz, Summit’s chief business and strategy officer, remembers being told. The drug, ivonescimab, was aimed at a “boring set of targets” — PD-1 and VEGF — that existing medicines already addressed, he recalled hearing.Summit was convinced ivonescimab had more to offer. Its belief was validated last year, when the drug outperformed Merck & CO.'s Keytruda, the industry’s dominant cancer immunotherapy, in a clinical trial.Practically overnight, Summit’s results made drugs like ivonescimab the next big thing in oncology. Summit is now the leader in a fast-moving race that already involves several …...
Votes:
5
0
Quantexa News
01/17
Checkpoint Therapeutics Inc (CKPT) Shares Decline Despite Market Challenges
The stock of Checkpoint Therapeutics Inc (NASDAQ: CKPT) has decreased by -3.45 when compared to last closing price of 3.33.Despite this, the company has seen a gain of 1.74% in its stock price over th...
Yahoo Finance Community
01/17
Comment
From getting manufacturing/supply in order etc it can take a smaller company 6+ weeks to launch after approval. TGTX took a while and their CEO is our chairman… now factor in partnership or BO and those do take a while through negotiation to signed deal. Look at one of the more recent approved oncology BO in Immunogen. Process started in spring 23 and Abbvie came into negotiations in the fall eventually making the best offer....
Votes:
2
0
Quantexa News
01/18
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Stock Has Dropped -6.19% Over The Month – Is There Room For Growth?
Checkpoint Therapeutics Inc (NASDAQ:CKPT)'s traded shares stood at 0.59 million during the last session, with the company's beta value hitting 1.37. At the close of trading, the stock's price was $3.1...
Quantexa News
01/19
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5%
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interes...
Quantexa News
01/19
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Expands By 17.5%
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 8,000,000 shares...
Quantexa News
01/19
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Grows By 17.5%
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 8,000,000 shares,...
Quantexa News
01/19
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Grows By 17.5%
Checkpoint Therapeutics, Inc. ( – ) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 8,000,000 shares, an increase of 17.5% from the December...
Quantexa News
01/20
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest...
Quantexa News
01/23
Evaluating the Ups and Downs of Checkpoint Therapeutics Inc's (CKPT) Stock
The stock of Checkpoint Therapeutics Inc (CKPT) has gone down by -12.62% for the week, with a -22.41% drop in the past month and a -7.97% drop in the past quarter. The volatility ratio for the week is...
Yahoo Finance Community
01/24
Comment
but why are there no funds inside this stock? none serious and all with low percentages and then one of the well-known bandits of finance? now it's all clear why it doesn't go up and what will happen to this stock, unfortunately I realized it late, there are no important funds and others have almost zero percentages,,,,, now it all explains, they understood well before how it ended that's why they didn't enter...
Quantexa News
01/25
Checkpoint Therapeutics Inc (NASDAQ: CKPT): Is It Possible To Be Down -6.25% YTD And Still Lose Money
During the last session, Checkpoint Therapeutics Inc (NASDAQ:CKPT)'s traded shares were 0.88 million, with the beta value of the company hitting 1.35. At the end of the trading day, the stock's price...
Quantexa News
01/28
Hodgkin's Lymphoma Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Checkpoint Therapeutics, Inc., Mundipharma Research Ltd., Aurigene Discovery Technologies Ltd., Immunitas Therapeutics, AstraZeneca, Tessa Therapeu
01-28-2025 08:02 PM CET | Health & Medicine Press release from: DelveInsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hodgkin's Lymphoma pipeli...
Yahoo Finance Community
01/29
Comment
2 months ago DERM (a FBIO child) received FDA approval for rosacea drug.. stock languished from 6 to 4... no partnership, no sale.. no announced plan to gia.. next week they will announce their commercialization plan. kinda sounds like ckpt ma have this act to follow...
Votes:
1
0
Yahoo Finance Community
01/30
Comment
Beginning to believe that management had literally done zero planning on a path forward once approved because they believed BP would scoop in and buy them out. We'll that didn't happen and what we are seeing now is the "deer in the headlight" reaction to BP not ringing the door bell....
Votes:
2
2
Yahoo Finance Community
01/30
Comment
You guys really think that the stock exchange price reflects the true value of the company ?Mark my Word : since FDA approval, the stock exchange price has nothing to do with real value. CKPT management cares less about it anymore they are up to a bigger thing.Take care and wait : this should not take long...
Votes:
5
0
Quantexa News
01/31
FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Evidence for efficacy is based on the results from the Study CK-301-101 On 13 December 2024, the US Food and Drug Administration (FDA) approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, In...
Yahoo Finance Community
01/31
Comment
An email reply from Sandya Von Der Weid from LifeScience Advisors that was posted on another CKPT stock forum. Dear Andrew, Thanks for reaching out. The company expects to execute on a partnership or other corporate development transaction to enable the commercialization of UNLOXCYT. The company is funded to complete this process and has no current plans to raise additional funds via an equity offering. A press release will be issued when there is news to share. Best, Sandya...
Votes:
5
0
Yahoo Finance News
02/03
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14% editorial-team@simplywallst.com (Simply Wall St) Mon, Feb 3, 20...
Quantexa News
02/03
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%
editorial-team@simplywallst.com (Simply Wall St) 4 min read In this article Key Insights The considerable ownership by individual investors in Checkpoint Therapeutics indicates that they collectiv...
Yahoo Finance Community
02/03
Comment
When sp goes down, some people come on the boards and talk about “manipulators” playing games with the retail and causing the price to go down. If that were true, then it would only be prudent to think the same “manipulators” could be playing games with the retail when the sp goes up and there is no news, on a very red day for pretty much the rest of the market! No?...
Votes:
1
0
Quantexa News
02/04
Navigating the Volatility of Checkpoint Therapeutics Inc's (CKPT) Stock
In the past week, CKPT stock has gone up by 10.45%, with a monthly decline of -0.94% and a quarterly plunge of -12.43%. The volatility ratio for the week is 5.61%, and the volatility levels for the la...
Yahoo Finance Community
02/04
Comment
As per Merck's quarterly report :"KEYTRUDA Sales Grew 18% to $29.5 Billion" I think the recent rise has lots to do with this update, as mentioned by others. UNLOXCYT has better results and much fewer side-effects. Even if Merck pays $5 billion for acquisition, they still get multiple of that in financial return....
Quantexa News
02/05
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%
editorial-team@simplywallst.com (Simply Wall St) 4 min read In This Article Key Insights The considerable ownership by individual investors in Checkpoint Therapeutics indicates that they collectiv...
Quantexa News
02/05
Checkpoint Therapeutics Inc (CKPT) Stock: More Robust Than the Numbers Suggest?
D. Boral Capital has recently initiated Checkpoint Therapeutics Inc (CKPT) stock to Buy rating, as announced on January 13, 2025, according to Finviz . Earlier, on July 14, 2022, B. Riley Securities h...
Yahoo Finance Community
02/06
Comment
certainly there is reason to applaud the way they have made the chickens bite by making them believe that the right moment had arrived and instead it is the usual move that allows them to reopen short waiting for the shares that will be given to them by the CEO through an issue at a much lower price than this, that fund is good at these things and is in there on purpose waiting for the gift, other than partnership or purchase by Mark or others...
Yahoo Finance Community
02/06
Comment
I think they have the cash runway to continue operations for 8-12 months without dilution. All the major lifting is done. As another poster commented, a strategic partnership is in the works, and the future licensee will likely emerge after their next earnings call or ex-dividend date....
Votes:
1
2
Quantexa News
02/07
No matter how cynical the overall market is Checkpoint Therapeutics Inc (CKPT) performance over the last week is recorded 24.30%
Checkpoint Therapeutics Inc (NASDAQ: CKPT) started the day on Thursday, with a price decrease of -5.36% at $3.53, before settling in for the price of $3.73 at the close. Taking a more long-term approa...
Quantexa News
02/07
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray Sells 74,110 Shares
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was sold at an ave...
Quantexa News
02/07
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 74,110 Shares of Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was sold at an...
Quantexa News
02/08
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $271,983.70 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CFO William Garrett Gray sold 74,110 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at...
Quantexa News
02/08
Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 74,110 Shares of Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was sold at an av...
Yahoo Finance Community
02/09
Comment
This is a disaster for Merck’s Revenue if Summit’s claims are true and gets FDA approval . The question is , IF CKPT’s COSI approved drug is better than Summit’s TRIAL drug ( not approved yet by FDA) and Better than Keytruda also ? CKPT better make a deal with Merck adap...
Votes:
1
1
Yahoo Finance Community
02/10
Comment
Summit's drug - a bispecific antibody - is not a fit for all approach. Why? The antibody's dual concept includes blocking the PD-1 activation on cytotoxic lymphocytes and prevents that these become anergic, thus accepting the tumor. That is like Keytruda works. However, the second mechanism, blocking neovascularization, is outdated. This class of drugs (prevention of new blood vessel formation) did, although promising in early stages, fail to deliver an improvement on long-term curative results in the tumor context, thus are a niche application for patients with EGFR-mutations such as EGFR amplification. This concept is restricted to slow down tumor growth, but it is also fostering post treatment tumor resistance, but this does not matter in 2L or 3L treatment....
Votes:
5
0
Yahoo Finance Community
02/10
Comment
More feed on that. The PD-L1 inhibition acts on the tumor cell (impairing the option of the tumor cell to switch off the approaching lymphocytes), while the PD-1 inhibition acts on the lymphocytes, shielding them from getting switched off. Thus, the latter, makes all lymphocytes at any site in the body more "aggressive" - and this change is the reason for the mentioned off target effects (inflammatory excursion on any organ) of anti-PD-1 antibodies....
Votes:
5
1
Yahoo Finance Community
02/11
Comment
Bluebird Bio and Checkpoint seem to be in similar positions both have new drugs both not divulging any information with investors both look very promising but with little cash runway left . Bluebird at least is treating patients now so they are a little further along. I'm an optimist and bullish on both....
Votes:
1
0
Yahoo Finance Community
02/11
Comment
It's clear that they want to get rid of the small shareholders and since there are no funds inside, they will be successful in a dilution that will wipe them out definitively. Their game is that and with the fund that is shorting ready to cover itself below 2 dollars because that's where it will end up, the small shareholders will be wiped out and they and the fund will have their pockets ful...
Votes:
3
6
Yahoo Finance Community
02/11
Comment
Vanguard increased their position and Goldman started a new one from Q4 filings. I’ve told y’all they are shaking the tree and people selling are giving them cheap shares. Wait until end of Q1 when they have to file we will see even more institutions have added....
Votes:
6
0
Quantexa News
02/11
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $32,542.65 in Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 10,331 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an...
Quantexa News
02/11
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 9,233 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at...
Quantexa News
02/11
James F. Oliviero III Sells 9,233 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 9,233 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at...
Quantexa News
02/12
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 9,233 Shares
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 9,233 shares of Checkpoint Therapeutics stock in a transaction that occurred on Friday, February 7th. The s...
Quantexa News
02/12
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 10,331 Shares
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 10,331 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an...
Quantexa News
02/12
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 9,233 Shares
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 9,233 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an av...
Quantexa News
02/12
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $32,542.65 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 10,331 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an a...
Quantexa News
02/12
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 9,233 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an...
Quantexa News
02/13
James F. Oliviero III Sells 10,331 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at...
Yahoo Finance Community
02/13
Comment
10,000 shares now reaches a easy $1,000,000 by 2027 eoy. Don't be fooled by the sp today. Shorts, bashers and competition are trying hard to scare you away. It's impossible now with FDA approval and pipe line of newer meds coming. Don't look back with regrets!...
Votes:
2
0
Quantexa News
02/14
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 9,233 shares of Checkpoint Therapeutics stock in a transaction dated Friday, February 7th. The stock was so...
Quantexa News
02/14
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) CEO James F. Oliviero III sold 9,233 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at a...
Yahoo Finance Community
02/14
Comment
Don't be fooled by shorts and bashers. They've already lost. Below is from Etrade's stats.Etrade 2026 eps $.92, 2027 eps $5.99 with revenue 900+million. Consertive estimate of PE=30 in 2026 gives a share price of $30. PE=30 in 2027 gives a share price of $179. That's very conservative estimates for a company with ckpt's potential. 10,000 shares now makes $1,970,000 by end of 2027. Hold and count yourself lucky for it....
Votes:
3
0
Quantexa News
02/16
PUREfi Wealth LLC Invests $32,000 in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
PUREfi Wealth LLC bought a new position in shares of Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) in the fourth quarter, according to the company in its most recent filing with the SEC....
Quantexa News
02/16
PUREfi Wealth LLC Takes Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
PUREfi Wealth LLC purchased a new stake in shares of Checkpoint Therapeutics, Inc. ( – ) during the fourth quarter, reports. The institutional investor purchased 10,000 shares of the company's stock,...
Yahoo Finance Community
02/16
Comment
While it seems that institutions are slowly increasing their stake, I ‘m wondering why the pps has not being going up more than it did after approval.One explaination is the impatient retail shareholders. Like one wise man used to say “The stock market is a device for transferring money from the impatient to the patient.”...
Votes:
2
0
Yahoo Finance Community
02/16
Comment
the drug was approved in December 2024 the shares that I see here on yahoo of the institutional ones as of December 31, 2024 are ridiculous all around 0.oo and so? it seems to me that no one is buying given also the low daily volumes it seems to me a lot like the arrival of stock emissions only to cover the fund of financial bandits that are inside.... I smell something burning...
Quantexa News
02/17
Gladstone Institutional Advisory LLC Boosts Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Gladstone Institutional Advisory LLC boosted its holdings in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) by 75.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 61,...
Quantexa News
02/17
Gladstone Institutional Advisory LLC Raises Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Gladstone Institutional Advisory LLC grew its holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) by 75.4% during the fourth quarter, according to the company in its most recent fili...
Yahoo Finance Community
02/17
Comment
Still accumulating this wealth monster. Looking at Etrade estimates 2026 eps (.92) and 2027 eps (5.99) I'm positioning myself for early retirement. Should easily support a PE=40 by then with some of the best revenue the market has seen in years. That's a nice sum of $ 2,396,000 on a $33,000 investment. Go Christopher, YEA...
Votes:
2
1
Yahoo Finance Community
02/17
Comment
Competitor MERCK is falling by leaps and bounds big time . Keytruda facing competition from summit Therapeutics and CKPT . They should buy CKPT at 2 X yearly Keytrudasales or $30-50 BILlUOn and corner the market . Otherwise competition will buy it and MRK will implode as down already z...
Votes:
1
1
Yahoo Finance Community
02/22
Comment
These are lack of info and high uncertainty times but looking at Checkpoints CEO background, he was instrumental of pushing a company to 1B in market capitalization in the past. If you look at Checkpoint they grinded to get that drug approved even through a CRL. Given that tenacity I don't fear they won't push this drug to the market. They surly would realize dilution is needed right after approval to go alone but non of that happened. This to me would indicate that there is not only hope but something in the works since at least December. Worst case this drug will make it to the market with lesser known partner or licensing deal. If I was to bet who among big Pharma was to partner with them is AstraZeneca. FBIO has partnership with them for CAEL and Olivero seem to have good connection with them....
Votes:
3
0
Yahoo Finance Community
02/22
Comment
Right now the only sensual partner is Merck. Keytruda coming off parent and 19 additional cancer indications with expiration in 2027 . MRK’s $29 BILLIONin annual sales must be protected at any cost !!! Pay $10-$15 billion for COsI. Keep off the market for Two years and go for many indications . Everyone wins . MRK guts to egotistical to figure this out .!! No one else benefits as much as MERCK !!!...
Yahoo Finance Community
02/23
Comment
With a large proportion of float still in hands of retail shareholders, I wouldn’t be surprised that current wait is also aimed at keeping morale and stock price low … and btw all my shares have been borrowed as if some fund wanted to put downward pressure on the stock after approval.When time comes, which shouldn’t be too long by now, some will even be happy to leave the boat for a mear 5$, missing the larger premium to be expected and allow the float to switch hands at a cheaper cost for the buyer....
Votes:
3
2
Quantexa News
03/03
Checkpoint Therapeutics Inc (CKPT) last year's performance of 33.64% is a clear signal for an entertaining trading season.
A new trading day began on Friday, with Checkpoint Therapeutics Inc (NASDAQ: CKPT) stock price up 5.54% from the previous day of trading, before settling in for the closing price of $2.71. CKPT's pric...
Quantexa News
03/04
https://seekingalpha.com/article/4764190-checkpoint-therapeutics-pivoting-from-approval-to-gutsy-next-shot-on-goal
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ) is a biotech that recently gained the first approval for a new PD-L1 inhibitor in an uncommon form of skin cancer. Despite now being a commercial-stage co...
Quantexa News
03/06
Checkpoint Therapeutics (NASDAQ:CKPT) Shares Pass Below Fifty Day Moving Average - Here's Why
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.17 and traded as...
Quantexa News
03/06
Checkpoint Therapeutics (NASDAQ:CKPT) Shares Pass Below Fifty Day Moving Average – Here's Why
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $3.17 and traded a...
Quantexa News
03/06
Checkpoint Therapeutics Inc (CKPT) Shares Decline Despite Market Challenges
Checkpoint Therapeutics Inc (NASDAQ: CKPT) has seen a decline in its stock price by -5.32 in relation to its previous close of 2.63. However, the company has experienced a -10.43% decline in its stock...
Quantexa News
03/09
CHECKPOINT THERAPEUTICS, INC. India's Sun Pharma to acquire Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid...
Quantexa News
03/09
CHECKPOINT THERAPEUTICS, INC. India's Sun Pharma to acquire Checkpoint Therapeutics
(Reuters) -India's Sun Pharmaceutical Industries said on Monday that it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 m...
Quantexa News
03/09
India's Sun Pharma to buy Checkpoint Therapeutics for $355 mln
Investing.com-- Sun Pharmaceutical (TADAWUL: ) Industries Ltd. (NSE: SUN ) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ: CKPT )- a Nasdaq-listed immunotherapy and oncology firm-...
Quantexa News
03/09
Sun Pharmaceutical Industries Agrees To Acquire Checkpoint Therapeutics
Sun Pharmaceutical Industries Limited agreed to acquire Checkpoint Therapeutics Inc. ( CKPT ), an immunotherapy and targeted oncology company. As per the deal, Checkpoint stockholders will receive, f...
Quantexa News
03/09
India's Sun Pharma to buy Checkpoint Therapeutics for $355 mln
Investing.com-- Sun Pharmaceutical (TADAWUL: ) Industries Ltd. (NSE: SUN ) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ: CKPT )- a Nasdaq-listed immunotherapy and oncology firm-...
Quantexa News
03/09
India's Sun Pharma to buy Checkpoint Therapeutics for $355 mln
Investing.com-- Sun Pharmaceutical (TADAWUL: ) Industries Ltd. (NSE: SUN ) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ: CKPT )- a Nasdaq-listed immunotherapy and oncology firm-...
Quantexa News
03/09
India's Sun Pharma to buy Checkpoint Therapeutics for $355 mln
Investing.com-- Sun Pharmaceutical (TADAWUL: ) Industries Ltd. (NSE: SUN ) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ: CKPT )- a Nasdaq-listed immunotherapy and oncology firm-...
Quantexa News
03/09
India's Sun Pharma to buy Checkpoint Therapeutics for $355 mln
Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm-...
Quantexa News
03/09
CHECKPOINT THERAPEUTICS, INC. India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid...
Quantexa News
03/09
Top India Drugmaker Sun to Buy US Oncology Firm for $355 Million
Sun Pharmaceutical Industries Ltd. has agreed to buy US-based immunotherapy and oncology firm Checkpoint Therapeutics Inc. for an upfront payment of $355 million, as India's largest drugmaker bolsters...
Quantexa News
03/09
Sun Pharma to acquire Nasdaq-listed oncology firm Checkpoint Therapeutics for $335 million
Checkpoint stockholders will also receive a contingent value right for up to $0.70 per share on achievement of certain milestone Sun Pharmaceutical Industries Ltd and Nasdaq-listed Checkpoint Therape...
Quantexa News
03/09
Sun Pharma To Acquire US Cancer Treatment Provider Checkpoint Therapeutics For Rs 3,084 Crore
S un Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint Therapeutics, Inc. for up to $355 million or Rs 3,084 crore. Checkpoint is a Mass...
Quantexa News
03/09
Sun Pharma expands oncology portfolio with Checkpoint Therapeutics acquisition
Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics, Inc. announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted on...
Quantexa News
03/10
Sun Pharma to acquire Checkpoint Therapeutics Inc, for a consideration of upto $355 million
Mumbai-based Sun Pharmaceutical Industries has entered into an agreement with Checkpoint Therapeutics Inc, to acquire the immunotherapy and targeted-oncology company for a consideration of up to $355...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
March 10, 2025 at 01:13 AM EDT The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click...
Quantexa News
03/10
Latest News | Sun Pharma to Acquire Checkpoint Therapeutics Inc for Up to USD 355 Mn
Get latest articles and stories on Latest News at LatestLY. Sun Pharmaceutical Industries on Monday said it will acquire immunotherapy and targeted oncology firm Checkpoint Therapeutics, Inc for up to...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
By: Ademi & Fruchter LLP via Business Wire The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Ph...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
Decatur, IN Today Clear skies. Low around 35F. Winds SW at 5 to 10 mph.. Tonight Clear skies. Low around 35F. Winds SW at 5 to 10 mph. Symbols Recent Quotes View Full List My Watchlist Cr...
Quantexa News
03/10
Checkpoint Therapeutics Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders (Businesswire)
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click here to learn how to join our...
Quantexa News
03/10
CHECKPOINT THERAPEUTICS, INC. Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click here to learn how to join our in...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click here to learn how to join our in...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Mar 10, 2025-- The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Ph...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click here to learn how to join our in...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--( BUSINESS WIRE )--The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click he...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders 10:13 PM on Sunday, March 9 The Associated Press MILWAUK...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click here to learn how to join our in...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click here to learn how to join our in...
Quantexa News
03/10
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million
Sun Pharmaceuticals Industries Ltd said on Monday, March 10, that it will buy Checkpoint Therapeutics, Inc, a Nasdaq-listed firm focused on immunotherapy and targeted therapies for oncology. Under the...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--( BUSINESS WIRE )-- The Ademi Firm is investigati...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE --(BUSINESS WIRE) The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma Click her...
Quantexa News
03/10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
Weather Alert ...RED FLAG WARNING IN EFFECT FROM 1 PM TO 7 PM CDT MONDAY FOR DRY AND WINDY CONDITIONS FOR PORTIONS OF SOUTHEAST KANSAS AND SOUTHWEST MISSOURI... The National Weather Service in Spring...
Quantexa News
03/10
Latest News | Sun Pharma Shares Rise over 2 Pc as Company to Acquire Checkpoint Therapeutics
Get latest articles and stories on Latest News at LatestLY. Shares of Sun Pharmaceutical Industries rose a little over 2 per cent in the morning trade on Monday after the company announced that it wil...
Quantexa News
03/10
Sun Pharma shares rise over 2 pc as company to acquire Checkpoint Therapeutics
N ew Delhi, Mar 10 (PTI) Shares of Sun Pharmaceutical Industries rose a little over 2 per cent in the morning trade on Monday after the company announced that it will acquire US-based Checkpoint Thera...
Quantexa News
03/10
Sun Pharma to acquire 100 pc stake in Checkpoint Therapeutics
Mumbai, Mar 10 (UNI) Pharma Major Sun Pharma has entered into an agreement for the acquisition of all the outstanding shares of Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology co...
Quantexa News
03/10
Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics
Shares of Sun Pharmaceuticals Industries Ltd were trading in the green and 2% higher on 10 March after the company announced its plans to acquire Checkpoint Therapeutics, Inc., a Nasdaq-listed immunot...
Quantexa News
03/10
Sun Pharma to acquire Checkpoint Therapeutics Inc for up to USD 355 mn
NEW DELHI, Mar 10: Sun Pharmaceutical Industries on Monday said it will acquire immunotherapy and targeted oncology firm Checkpoint Therapeutics, Inc for up to USD 355 million. As per the pact inked...
Yahoo Finance News
03/10
Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical MT Newswires Mon, Mar 10, 2025, 3:14 AM...
Quantexa News
03/10
Sun Pharma to acquire Waltham, Massachusetts-based Checkpoint Therapeutics
Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics, Inc. announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted on...
Yahoo Finance News
03/10
Sun Pharma agrees to acquire Checkpoint Therapeutics
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Sun Pharma agrees to acquire Checkpoint Therapeutics On the transaction’s closure · Pharmaceutical Technology · Nils...
Quantexa News
03/10
CHECKPOINT THERAPEUTICS, INC. Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma
By Colin Kellaher Shares of Checkpoint Therapeutics surged in premarktet trading Monday after the immunotherapy and targeted oncology company agreed to be acquired by Indian pharmaceutical giant Sun...
Yahoo Finance News
03/10
Top India Drugmaker to Buy US-Based Checkpoint for $355 Million
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Top India Drugmaker to Buy US-Based Checkpoint for $355 Million Satviki Sanjay Mon, Mar 10, 2025, 3:46 AM 2 min read...
Quantexa News
03/10
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
Shares of Checkpoint Therapeutics, Inc. CKPT rose sharply in today's pre-market trading. Sun Pharma announced plans to acquire Checkpoint Therapeutics in a $355 million deal. Checkpoint Therapeutics...
Quantexa News
03/10
Sun Pharma to acquire Checkpoint Therapeutics for USD 355 million
Mumbai: Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics, Inc. have announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy an...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
March 10, 2025 at 08:05 AM EDT Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limite...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Mar 10, 2025-- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Indust...
Quantexa News
03/10
CHECKPOINT THERAPEUTICS, INC. CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a cont...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Skip to main content Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.1...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a cont...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a cont...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a cont...
Quantexa News
03/10
Sun Pharma to buy US-based oncology firm with new skin cancer treatment product for $355 million
S un Pharmaceutical Industries Ltd is buying US-based immunotherapy and oncology firm Checkpoint Therapeutics Inc. for $355 million. This is also Sun Pharma's second acquisition in less than three mo...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a cont...
Quantexa News
03/10
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited f...
Quantexa News
03/10
Sun Pharma expands oncology portfolio, acquires Checkpoint Therapeutics
Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics, Inc. announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted on...
Quantexa News
03/10
Sun Pharma Expands Oncology Portfolio with Checkpoint Therapeutics Acquisition
Sun Pharmaceutical Industries Limited has announced a significant expansion of its oncology portfolio through the acquisition of Checkpoint Therapeutics, Inc., a U.S.-based immunotherapy and targeted...
Yahoo Finance News
03/10
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details Vandana Singh Mon, Mar 10, 2025, 11:08...
Quantexa News
03/10
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted onco...
Quantexa News
03/10
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details
Vandana Singh 2 min read In this article On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company Checkpoint Therapeutic...
Quantexa News
03/10
Checkpoint Therapeutics Target of Unusually Large Options Trading (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw unusually large options trading activity on Monday. Stock traders bought 5,081 call options on the stock. This represents an increase...
Quantexa News
03/10
Checkpoint Therapeutics Target of Unusually Large Options Trading (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) saw unusually large options trading activity on Monday. Stock traders bought 5,081 call options on the stock. This represents an increas...
Yahoo Finance News
03/10
Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monda...
Yahoo Finance News
03/10
Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target MT Newswires Mon, Mar 10...
Quantexa News
03/10
CHECKPOINT THERAPEUTICS, INC. Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid...
Quantexa News
03/10
CHECKPOINT THERAPEUTICS, INC. Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid...
Quantexa News
03/10
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details
On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc. CKPT for an upfront cash payment of...
Quantexa News
03/10
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CKPT, RDFN, BLBX on Behalf of Shareholders
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT)'s sale to Sun Pharmaceutical Industries Limited for per share and a contingent value right for up to per share on achievement of a milestone. If you are a...
Yahoo Finance News
03/10
Sector Update: Health Care Stocks Decline Monday Afternoon
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Sector Update: Health Care Stocks Decline Monday Afternoon MT Newswires Mon, Mar 10, 2025, 2:02 PM 1 min rea...
Quantexa News
03/10
https://seekingalpha.com/article/4766197-checkpoint-agrees-to-sun-pharma-buyout-this-deal-suits-both-parties
Summary Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, Inc. for $4.10 per share, a 65% premium to last traded price, post-FDA approval of Unloxcyt for metastatic cutaneo...
Quantexa News
03/10
CHECKPOINT THERAPEUTICS, INC. The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
March 10, 2025 at 04:46 pm EDT NEW YORK March 10, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized a...
Quantexa News
03/10
Checkpoint Therapeutics SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT (PR Newswire)
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT PR Newswire NEW YORK, March 10, 2025 NEW YORK , March 10, 2025 /PRNewswire/ -- Montever...
Quantexa News
03/10
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
NEW YORK March 10, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS...
Quantexa News
03/10
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
PR Newswire NEW YORK, March 10, 2025 NEW YORK March 10, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recog...
Quantexa News
03/10
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
We and our partnersstore and/or access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised adverti...
Quantexa News
03/10
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
PR Newswire Today at 9:45pm GMT+1 SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT PR Newswire NEW YORK, March 10, 2025 NEW YORK Marc...
Quantexa News
03/10
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
NEW YORK March 10, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS...
Quantexa News
03/10
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc. - CKPT
NEW YORK, March 10, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
News provided by NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT ) to Sun...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Ind...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK, March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceuti...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
PR Newswire NEW YORK, March 10, 2025 NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Jul
NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: ) to Sun Pharmaceutical Industr...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Ind...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Ind...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
PR Newswire Today at 11:41pm GMT+1 NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Na...
Quantexa News
03/10
Exploring Checkpoint Therapeutics and Its Future with Sun Pharma
Checkpoint Therapeutics: A New Chapter with Sun Pharma Recently, Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) has been at the center of attention following its proposed sale to Sun Pharmaceutical Ind...
Quantexa News
03/10
Checkpoint Therapeutics CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders (Businesswire)
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a cont...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK, March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceuti...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma By Julie & Holleman LLP Mar 10, 2025 1 hr ago
NEW YORK March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Ind...
Polygon News
03/10
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CKPT, RDFN, BLBX on Behalf of Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales of Che...
Quantexa News
03/10
Sun Pharmaceutical to Acquire Checkpoint Therapeutics for $355M
Waltham, Mass.-based Checkpoint Therapeutics Inc. (Nasdaq: CKPT) has agreed to be acquired by India-based Sun Pharmaceutical Industries Ltd. for $355 million to expand its specialty therapy portfolio,...
Quantexa News
03/10
Investigation of CKPT, RDFN, and BLBX: Impact on Shareholders
Exploring Shareholder Rights in Recent Company Transactions Halper Sadeh LLC is actively investigating three notable companies, focusing on shareholder rights and potential breaches related to recent...
Quantexa News
03/10
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK, March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceuti...
Quantexa News
03/10
Sun Pharma to Acquire Checkpoint Therapeutics
(PRNewsfoto/Sun Pharmaceutical Industries Inc., USA (Sun Pharma)) Hand-out MUMBAI, India and WALTHAM, Mass., /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN,...
Quantexa News
03/10
Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics
Sun Pharmaceutical Industries and Checkpoint Therapeutics, Inc. today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted onco...
Quantexa News
03/11
Traders Buy Large Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) was the target of some unusual options trading on Monday. Investors purchased 5,081 call options on the stock. This represents an increase...
Quantexa News
03/11
Sun Pharma to acquire oncology therapy company Checkpoint in US
Sun Pharmaceutical Industries Ltd has entered into an agreement to acquire US-based immunotherapy and targeted oncology company, Checkpoint Therapeutics Inc, a development that would bring the only FD...
Quantexa News
03/11
Sun Pharmaceutical Industries Agrees To Acquire Checkpoint Therapeutics
(RTTNews) - Sun Pharmaceutical Industries Limited agreed to acquire Checkpoint Therapeutics Inc. (CKPT), an immunotherapy and targeted oncology company. As per the deal, Checkpoint stockholders will...
Quantexa News
03/11
Major Acquisition Deal in Pharmaceutical Industry: Sun Pharma to Acquire Checkpoint Therapeutics
This website uses cookies to ensure you get the best experience on our website. Learn more Over the past year, the stock has seen a modest return of 0.2 per cent. However, over a three-year period, i...
Yahoo Finance News
03/11
HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target MT Newswires Tue, Mar...
Quantexa News
03/11
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT) regarding possible breaches of fiduciary duti...
Quantexa News
03/11
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT) regarding possible breaches of fiduciary duti...
Quantexa News
03/11
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
March 11, 2025 12:10 PM EDT Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT ) regarding possi...
Quantexa News
03/11
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT) regarding possible breaches of fiduciary duti...
Quantexa News
03/11
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 11, 2025) - Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT) regarding possible breaches of fiduciary duti...
Quantexa News
03/11
An In-Depth Look At Checkpoint Therapeutics Inc (CKPT)
Checkpoint Therapeutics Inc (NASDAQ:CKPT) has a beta value of 1.23 and has seen 2.28 million shares traded in the recent trading session. The company, currently valued at $196.06M, closed the recent t...
Quantexa News
03/12
Checkpoint Therapeutics Sees Unusually High Options Volume (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Get Free Report ) was the recipient of unusually large options trading activity on Monday. Traders acquired 5,081 call options on the stock. This represen...
Quantexa News
03/12
Sun Pharma to Acquire Checkpoint Therapeutics in Oncology Expansion
Sun Pharmaceutical Industries Limited (Sun Pharma) has announced an agreement to acquire Checkpoint Therapeutics, Inc. (Checkpoint), a Nasdaq-listed immunotherapy and targeted oncology company. This s...
Quantexa News
03/12
Checkpoint Therapeutics Inc (CKPT) up 25.00% since start of the year
Checkpoint Therapeutics Inc (NASDAQ: CKPT) is 25.00% higher on its value in year-to-date trading and has touched a low of $1.38 and a high of $4.50 in the current 52-week trading range. The question b...
Quantexa News
03/12
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Checkpoint Therapeutics, Inc. (Nasdaq - CKPT), Redfin Corporation (Nasdaq - RDFN), Amplify Energy Corp. (NYSE - AMPY), Blackboxstocks Inc. (Nasdaq - BLBX)
BALA CYNWYD, Pa., March 12, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/12
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Checkpoint Therapeutics, Inc. (Nasdaq - CKPT), Redfin Corporation (Nasdaq - RDFN), Amplify Energy Corp. (NYSE - AMPY), Blackboxstocks Inc. (Nasdaq - BLBX)
Decatur, IN Today Some clouds. Low around 30F. Winds ENE at 5 to 10 mph.. Tonight Some clouds. Low around 30F. Winds ENE at 5 to 10 mph. Symbols Recent Quotes View Full List My Watchlist...
Polygon News
03/12
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, CKPT, AMPY on Behalf of Shareholders
Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties by Paragon 28, Inc., Checkpoint Therapeutics, Inc., and Amplify Energy Corp. in relat...
Quantexa News
03/12
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Checkpoint Therapeutics, Inc. (Nasdaq - CKPT), Redfin Corporation (Nasdaq - RDFN), Amplify Energy Corp. (NYSE - AMPY), Blackboxstocks Inc. (Nasdaq - BLBX)
BALA CYNWYD, Pa., March 12, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/12
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Checkpoint Therapeutics, Inc. (Nasdaq - CKPT), Redfin Corporation (Nasdaq - RDFN), Amplify Energy Corp. (NYSE -
March 12, 2025 4:06 PM EDT BALA CYNWYD, Pa., March 12, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigat...
Quantexa News
03/13
10,081 Shares in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Bought by SBI Securities Co. Ltd.
SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) during the fourth quarter, according to its most recent 13F filing with the Securities and E...
Quantexa News
03/13
SBI Securities Co. Ltd. Takes Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
SBI Securities Co. Ltd. purchased a new position in Checkpoint Therapeutics, Inc. ( NASDAQ:CKPT – Free Report ) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 10,081 shares of...
Polygon News
03/13
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options
Kaskela Law LLC is investigating the fairness of Checkpoint Therapeutics, Inc.'s proposed acquisition by Sun Pharmaceutical Industries Ltd. at $4.10 per share plus a contingent value right, as the buy...
Quantexa News
03/13
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of...
PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDA...
Quantexa News
03/13
Investigating the Buyout of Checkpoint Therapeutics: Key Insights
Understanding the Checkpoint Therapeutics Buyout Offer Recently, the financial landscape surrounding Checkpoint Therapeutics, Inc. has shifted dramatically with the announcement of its buyout by Sun...
